Balance between maternal antiviral response and placental transfer of 1 2 protection in gestational SARS-CoV-2 infection 3 Juliana Gonçalves¹, Magda Melro¹, Marta Alenguer², Catarina Araújo³, Júlia 4 Castro-Neves¹, Nádia Charepe^{3,4}, Fátima Serrano^{3,4}, Carlos Pontinha³, Maria 5 João Amorim², Helena Soares^{1,#} 6 7 ¹Human Immunobiology and Pathogenesis Laboratory, iNOVA4Health, Nova 8 9 Medical School | Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 10 Lisboa, Portugal ²Cell Biology of Viral Infection Lab, Instituto Gulbenkian de Ciência, Oeiras, 11 12 Portugal 13 ³Centro Hospitalar Universitário Lisboa Central, Lisboa, Portugal ⁴CHRC, Nova Medical School | Faculdade de Ciências Médicas, Universidade 14 15 Nova de Lisboa, Lisboa, Portugal 16 17 **Keywords**: COVID-19, SARS-CoV-2, pregnant, vertical transmission, maternal 18 infection, neutralizing antibodies, neonatal immunity, transplacental antibody transfer, NK cells 19 20 21 [#]Corresponding Author: Helena Soares, Laboratory of Human Immunobiology 22 and Pathogenesis, Rua Câmara Pestana, 6 1150-082 Lisbon, Portugal. 23 helena.soares@nms.unl.pt; +351 218 803 133 24

25 The authors have declared that no conflict of interest exists. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 Abstract

27 Maternal immune responses during pregnancy protect the growing fetus by clearing infection, preventing its vertical transmission, and through transplacental 28 29 transfer of protective immune mediators to the fetus. How maternal immune response balances SARS-CoV-2 antiviral responses with transplacental transfer 30 of protection to the fetus remains unclear. Our study shows that upon SARS-31 32 CoV-2 maternal infection, neutralizing antibodies (NAbs) are infrequently detected in cord blood. We uncovered that this is due to impaired IgG-NAbs 33 34 placental transfer in symptomatic infection and to the predominance of maternal 35 SARS-CoV-2 NAbs of the IgA and IgM isotypes, which are prevented from crossing the placenta. Crucially, the decision between favoring maternal antiviral 36 37 response or transplacental transfer of immune protection to the fetus appears to 38 hinge on the balance between IL-6 and IL-10 induced by SARS-CoV-2 infection, decreasing or increasing transplacental transfer of IgG-NAbs, respectively. In 39 addition, IL-10 inversely correlates with maternal NK cell frequency. Finally, we 40 found that ongoing infection favored perinatal transfer of maternal NK cells, 41 highlighting a maternal sponsored mechanism to protect the newborn from 42 43 horizontal transmission of infection. Our data point to an evolutionary trade-off 44 which at once optimizes maternal viral clearance and vertical transfer of immune 45 protection during the more susceptible perinatal period.

46 Brief Summary

In SARS-CoV-2 maternal infection, the balance between maternal antiviral response
and transplacental transfer of cellular and humoral (NAb) protection hinges on
maternal IL-6 and IL-10.

50

51 Introduction

52 Maternal immune response protects the growing fetus by clearing the pathogen preventing its vertical transmission, and via transplacental transfer of protective 53 cellular and humoral components to the fetus. This vertical transfer of protection 54 continues after birth through secretory IgA and IgM antibodies and immune cells 55 56 contained in breastmilk (1-3). Infections during gestation posit a challenge to the 57 orchestration between priming of the maternal immune response in the tissue affected and the delivery of maternal immune components to the offspring, 58 59 immediately via the placenta or posteriorly via breastmilk. The outcomes of 60 SARS-CoV-2 infection in pregnancy vary from asymptomatic or mildly symptomatic to severe disease (4-6), with increased levels of inflammatory 61 62 cytokines and immune cells being detected in maternal and cord blood samples 63 (7, 8). How these cellular and humoral immune mediators balance maternal anti-SARS-CoV-2 response with the transplacental transfer of protection to the fetus 64 remains to be addressed. 65

Maternal antibodies of the IgG isotype are transferred across the placenta from 66 gestational week 13 through active transport mediated by FcRn expressed on 67 68 synciciotrophoblasts (9). Due to their high molecular size and/or lack of specific transporters, maternal IgM and IgA antibodies are largely prevented from being 69 transferred to the fetus (10). Neutralizing antibodies (NAb) targeting spike protein 70 71 receptor-binding domain (RBD) have been shown to play an important role in 72 controlling SARS-CoV-2 infection (11–13). Recent works in COVID-19 recovered 73 individuals have put forward that SARS-CoV-2 neutralization is associated not 74 only with anti-RBD IgG but to a significant extent to anti-RBD antibodies of IgA and IgM isotypes (14–17), raising the guestions of how immune alterations during 75

76 pregnancy impact the breadth of NAbs isotypes and consequently how efficiently 77 they are transported across the placenta upon SARS-CoV-2 maternal infection. In addition to antibodies, immune cells and the cytokines they produce also play 78 79 a role in resolution of SARS-CoV-2 infection, including CD4⁺ T (18) and NK cells (19). Namely, NK cells compose 20% of lung lymphocytes and play an important 80 81 role in eliminating SARS-CoV-2 infected cells (19). Pregnancy leads to a 82 decrease in CD4⁺ T and NK cell levels in circulation (20). Nevertheless, increased frequency of NK cells has been detected in neonates born to pregnant women 83 with ongoing infection (8) and neonatal NK cells have been shown to display 84 85 antiviral response from birth (21). In COVID-19 patients the profile of inflammatory cytokine responses has been associated with disease outcomes. 86 87 While an interferon response is conducive to viral clearance (22), the enduring 88 production of inflammatory cytokines IL-1b, IL-6, IL-8, IL-10 and IL-18 has been linked to disease severity (23, 24). Pregnant women have been described to 89 90 mount a mild inflammatory response to SARS-CoV-2 infection that is reflected in 91 the fetus, even in the absence of vertical viral transmission, as previously observed for gestational HIV-1 and HBV infections (7, 8, 25, 26). 92

93 In view of the potential long-term harm to the developing fetus it is important to identify how long cytokines linger even after the infection has been cleared, the 94 extent that they are transferred to the fetus and to further document possible fetal 95 96 immune priming (8). Crucially, it remains to be addressed whether there is a 97 cellular component to SARS-CoV-2 transplacental transfer of immune protection 98 and crucially, the identification of the inflammatory networks regulating the 99 transfer of protective antibodies and immune cells from the infected mother to the 100 fetus.

101 In this study, we advance a role for NK cells and anti-spike IgM in balancing 102 maternal antiviral response with vertical transfer of immune protection. We identified that breadth of SARS-CoV-2 NAbs isotypes depended on gestational 103 104 age at the time of infection. While second or earlier third trimester SARS-CoV-2 NAbs were exclusively associated with anti-spike antibodies of IgA and IgM 105 106 isotypes, in ongoing infections NAbs correlated with anti-spike IgA, IgG and IgM. 107 In addition, we show that in symptomatic ongoing infections IgG-NAbs transplacental transfer in hindered. Consequently, we demonstrate that the 108 109 transfer of NAbs, but not of anti-spike IgG, to the fetus is impaired. The role of 110 anti-spike IgM antibodies and NK cells in gestational protection from SARS-CoV-111 2 infection is further highlighted by their association with asymptomatic maternal 112 infection. Mechanistically, we have put forward that the decision between favoring 113 maternal antiviral response or transplacental transfer of immune protection to the 114 fetus appears to hinge on the balance between IL-6, and IL-10. IL-6 and IL-10 115 are associated with decreased or increased IgG-NAbs transplacental transfer, 116 respectively. In addition, IL-10 inversely correlates with the frequency of maternal 117 NK cells, in circulation. By interpolating our experimental results with clinical data, 118 we identified that ongoing infection favored the transfer of maternal NK cells to 119 the neonate perinatally. Altogether our data support a two-pronged model, 120 whereby maternal immune responses might protect the neonate from both 121 vertical and horizontal SARS-CoV-2 transmission. First, through early NK cell and 122 IgM mediated viral clearance, preventing in utero viral transmission. Second, by 123 favoring a maternal sponsored mechanism to protect the newborn from horizontal transmission of infection, a time when close physical contacts between mother 124 125 and neonate together with neonate's immature immune system results in

- increased risk of infectivity. Our data support that this might be achieved not only
- 127 via perinatal transfer of NK cells, but crucially through the transfer of SARS-CoV-
- 128 2 NAbs of the IgA and IgM isotypes through breastmilk.

- **T** + 1

151 **Results**

152 **Population**

Our study comprised 72 pregnant women recruited from May 2020 to February 153 154 2021, before the introduction of COVID-19 vaccination to the general population. Sixty pregnant women tested positive (CoV-2⁺; Table 1) and 12 tested negative 155 156 (CoV-2⁻; Table 2) for SARS-CoV-2 by PCR on nasopharyngeal swabs (Figure 157 1A). Of the 60 SARS-CoV-2⁺ pregnant women, 9 tested positive in the second trimester (recovered second trimester group, 2R; Figure 1A), 11 tested positive 158 between 20 to 154 days before delivery (recovered third trimester group, 3R; 159 Figure 1A), and 40 tested positive in late 3rd trimester within 11 days of delivery 160 (ongoing third trimester infection group, 3O; Figure 1A). Fifty percent of pregnant 161 162 women were symptomatic, with four pregnant women being admitted to the 163 hospital due to COVID-19 symptomatology, non-invasive oxygen support was provided to the other three. Within the SARS-CoV-2⁺ population, 50 mother-164 165 umbilical cord matched samples were collected at the time of birth, and in 82% 166 of the deliveries a nasopharyngeal swab was performed to the newborn, with 3 babies testing positive but remained asymptomatic and one baby that tested 167 168 negative being admitted to neonatal ICU (Table 1). Additional 9 pregnant women were recruited between July of 2021 and February of 2022 having undergone 169 COVID-19 mRNA BNT162b2 vaccine. Maternal and cord blood samples were 170 171 collected from 6 dyads (Figure 1A; Table 3).

172

Poor neonatal NAbs titers are associated with maternal production of IgM NAbs and with impaired transplacental transfer of IgG-NAbs in
 symptomatic infections

176 The transfer of antibodies from maternal to fetal circulation relies on the neonatal 177 Fc receptor (FcRn) expressed on the placenta. Crucially, FcRn are capable of transporting antibodies of the IgG isotype, but not of the IgA nor IgM isotypes (9). 178 179 Hence, detection of IgA and IgM antibodies in cord blood is used as diagnostic for fetal infection (27). Out of 50 dyads, we only detected one case where both 180 181 anti-spike IgA and -IgM antibodies were present in cord blood (Figures S 1 A, B). 182 Anti-spike IgG was found in all mothers and neonates born to SARS-CoV-2+ mothers in the 2R and 3R groups and in 68.4% of mothers and 56.8% of neonates 183 born to SARS-CoV-2 mothers in the 3O group (Figure S1C). In SARS-CoV-2 184 185 recovered groups 2R and 3R, anti-spike and anti-RBD levels and titres (Figures 1 B, C) remained overall comparable within mother-neonate dyads, while there 186 187 was a significant decrease in anti-spike/RBD IgG in neonates born to mothers 188 with ongoing SARS-CoV-2 infection (Figures 1 B, C; 3O). Subsequently, the transfer ratios of anti-spike and anti-RBD IgG antibodies were ~1 in 2R and 3R 189 190 groups and ~0.5 in the 3O group (Figure 1D), with the efficiency of antibody 191 transfer increasing with time elapsed between SARS-CoV-2 infection and delivery (Figure 1E). We then addressed whether the sex of the fetus had an 192 193 impact on the immune response to infection. We did not observe any change in maternal production of anti-spike IgA, IgM or IgG antibodies in function of the sex 194 of the fetus (Figure S1D). However, in dyads with ongoing maternal SARS-CoV-195 196 2 infection, we observed a significant decrease in anti-spike IgG and anti-RBD in 197 male neonates (Figures 1F, S1E).

To gauge on how anti-SARS-CoV-2 antibodies operated during pregnancy, we compared the capacity of maternal and neonate's anti-spike antibodies to neutralize viral entry. Following SARS-CoV-2 infection, only 58.6% of mothers

201 and 10% of neonates possessed neutralizing antibodies (Figures 1 G, H), with 202 the frequency of detection of maternal neutralizing antibodies (Figure 1I) 203 decreasing with time elapsed since infection from ~60% in the 3R and 3O groups 204 to 44.4% in the 2R group, suggesting a possible waning of NAbs in infections 205 occurring in the second trimester. Of the 50 dyads tested, we could only detect 206 neutralizing antibodies in 5 neonates (IQR: 23-40; Figure 1J: CoV-2⁺). In contrast, 207 in vaccinated dyads, neutralizing antibodies were present in all neonatal blood samples (Figures 1 G, H) and their titers were similar within each dyad (Figure 208 209 1J; Vac). Infected and vaccinated mothers had equivalent neutralization titers 210 (Figure 1J), making it unlikely that the almost absence of NAbs in neonates was primarily due to failure of the infection to induce NAbs. Conversely to what we 211 212 had found for anti-spike IgG transplacental transfer (Figure 1E), the transfer ratio 213 of NAbs did not increase with time elapsed since infection (Figure S1F). We next 214 explored how disease presentation and the nature of maternal antibody response 215 affected NAbs transplacental transfer. First, as the RBD domain is particularly 216 enriched in neutralizing epitopes (11-13), we used anti-RBD antibodies as surrogates to get an insight of how disease presentation would affect NAbs 217 218 transplacental transfer. Presence of symptoms did not impact the maternal levels of anti-RBD nor of NAbs, including in study participants with ongoing infection 219 (Figures S1 G, H; 3O). Crucially, the transfer of anti-RBD antibodies, but not the 220 221 ones against trimeric spike protein, plumets by ~40% in symptomatic ongoing 222 maternal infection (Figure 1K). Anti-spike IgM and IgA have been associated with 223 SARS-CoV-2 neutralization in both COVID-19 disease and vaccination (14–16). 224 This raises the possibility that poor neutralizing response in neonates resulted from maternal neutralizing activity being, at least partly, mediated by IgM/IgA and 225

226 thus not transferrable to the neonate. To address this hypothesis, we correlated 227 the levels of maternal anti-spike IgA, -IgG and -IgM antibody with neutralization titers in ongoing infection and recovered groups. In ongoing infection, 228 229 neutralization titers correlated with all 3 anti-spike antibody isotypes (Figures 1L, 230 S1I) with anti-spike IgG correlating stronger with anti-spike IgA than with anti-231 spike IgM (Figures 1M, S1J). Furthermore, in ongoing infection neutralization was 232 stronger in mothers that displayed both anti-spike IgG and IgM antibodies, 233 compared to cases that only presented anti-spike IgG or anti-spike IgM (Figure 1N; 3O). Intriguingly, in recovered maternal infection, neutralizing antibody titers 234 235 correlated with anti-spike IgA and -IgM, but not with anti-spike IgG (Figures 10, S1 K; 2R+3R). In recovered infections, anti-spike IgG and -IgM did not correlate, 236 237 even though we detected an association between anti-spike IgG and -IgA 238 (Figures 1P, S1L). In recovered infection the presence of anti-spike IgG 239 antibodies alone was insufficient to enact neutralization (Figure 1Q). The 240 absence of maternal samples with anti-spike IgM but without anti-spike IgG, 241 made it impossible to evaluate whether successful neutralization could be achieved by IgM alone (Figure 1Q). In contrast, in COVID-19 vaccinated women, 242 243 neutralization appears to be associated with anti-spike IgG, but not with anti-spike IgM antibodies (Figure 1R), which is in agreement with the effective transfer to 244 the neonates of NAbs that we (Figure 1J; Vac) and others (28-30) have 245 246 observed.

These results indicate that sparse detection of NAbs in neonates is due to combined action of symptomatic infection particularly hindering IgG-NAbs placental transfer and of maternal production of IgA- and IgM-NAbs in response to SARS-CoV-2 infection.

251

252 Asymptomatic maternal infection is associated with increased early immune response comprised by anti-spike IgM and 253 NK cells. 254 To identify putative immune markers of infection outcomes, we analyzed 255 maternal and neonate's cellular response in asymptomatic versus symptomatic 256 ongoing maternal infections. As expected from the short interval spanned 257 between infection and sample collection, the maternal frequency of B cells, class-258 switch IgD⁻ B cells, CD4⁺ T cells, activated CD4⁺ T cells, CCR6⁺ T cells and CXCR5⁺ T cells remained equivalent across disease presentation (Figures 2 A-259 260 F, S2A). Interestingly, asymptomatic going infection gave rise to higher frequency 261 of NK cells in maternal circulation and in the cord blood, even though in the latter 262 case it did not reach statistical significance (Figures 2 G, H, S2A). The implication 263 that immediate immune response might be important to curtail infection, made us 264 look at rapidly produced IgM antibodies, and we found that anti-spike IgM levels 265 were indeed higher in asymptomatic ongoing infections (Figure 2I). 266 Upon interpolating our results with clinical data, we observed that, in mothers with ongoing infection, delayed umbilical cord clamping led to higher NK cell 267 268 frequency in neonates (Figure 2J). Pertinently, delayed clamping did not alter 269 neonatal frequency of B cells (Figure 2K) or CD4⁺ T cells (Figure 2L). Similarly, delayed clamping had no impact on neonatal NK cell frequency in resolved 270 271 SARS-CoV-2 infections (Figure 2M). 272 To pinpoint long-lasting cellular immune changes brought by SARS-CoV-2 infection, we compared the B and CD4⁺ T profiles in pregnant women that had 273 274 been infected or vaccinated at similar gestational ages. Delivery occurred at an average of 66.8 and of 73.9 days post diagnosis in 2R+3R groups or inoculation 275

276 of second vaccine dose, respectively. Upon maternal SARS-CoV-2 infection, the 277 frequency of B and CD4⁺ T cells was equivalent between SARS-CoV-2 infected and COVID-19 vaccinated group (Figures S2 A-C). When we looked in more 278 279 detail to CD4⁺ T cell activation and migratory status, we observed that SARS-CoV-2 infection did not alter CD4⁺ T cell activation state (Figure S2D) but led to 280 281 an increase in the frequency of CXCR5⁺ T cells, and to a lesser extent of CCR6⁺ T cells (Figure S2 E, F). Importantly, this increase in the frequency of maternal 282 CCR6⁺ and CXCR5⁺ T cells was not reflected in the fetus (Figures S2 G, H). 283 CXCR5⁺T cell expansion was proportional to the time elapsed between diagnosis 284 285 and delivery, in asymptomatic, but not in symptomatic, infections (Figure S2I). Despite CXCR5⁺ T cells role in directing antibody production (31), their expansion 286 287 was not associated with higher anti-spike IgG, IgA, or IgM levels (Figures S2 J-288 L).

Altogether, our results suggest that an early immune response conveyed by antispike IgM antibodies and NK cells is associated with asymptomatic maternal infection and that placental transfer of NK cells might consist of a maternal sponsored mechanism to protect the fetus from infection.

293

Maternal inflammatory response balances antibody placental transfer with NK cell expansion.

296 Cytokines are key players in coordinating a healthy pregnancy (32). 297 Nonetheless, inflammatory responses during pregnancy have been implicated in 298 pregnancy complications (32), decreased rate of IgG transplacental transfer (9), 299 and neurodevelopmental deficits (32). We performed a 13-cytokine multiplex 300 assay on plasma isolated from maternal and cord blood samples. To sort out

301 long-term from short-term cytokine alterations, we started by comparing the 302 inflammatory profile of mothers with recovered (2R+3R) or ongoing (3O) 303 infection. Mothers with ongoing infection exhibited higher levels of the anti-viral 304 mediator IFN- α 2, the inflammatory cytokines IL-33 and TNF- α , the anti-305 inflammatory cytokine IL-10, and the chemokine MCP-1 (Figure. 3A). To correct for cytokine alterations intrinsic to pregnancy and delivery (33), we compared the 306 307 inflammatory profiles of participants that had been either infected or vaccinated 308 at similar gestational age (Figure S3D). Maternal infection led to higher concentration of maternal IL-6 and IL-18, two cytokines that have been implicated 309 310 in pregnancy complications and preterm delivery (32), when compared to vaccination (Figure S3D). Of the analyzed cytokines, we observed positive 311 correlations between IL-12p40 and IFN-y, IL-23 and IL-17, and IL-23 and IL-18 312 313 (Figures S3 A-C). While maternal serum concentration of IFN-a2 and MCP-1 314 inversely correlated with time elapsed between infection and delivery (Figure 3B), 315 reinforcing their role in acute infection; elevation of inflammatory IL-6 and IL-18 316 was independent of time of infection (Figure. 3B). These data suggest that SARS-317 CoV-2 infection can lead to durable inflammatory responses long-after the 318 infection has been cleared.

Next, we sought to probe how the inflammatory response imparted on anti-RBD IgG transplacental transfer in ongoing infections (Figure 1L). We found that anti-RBD IgG transplacental transfer inversely correlated with IL-6 (Figure 3C), but positively correlated with IL-10 and with IL-23 (Figures 3 D, E). No association was detected between IL-6, IL-10, and IL-23 concentration and anti-RBD IgG or NT50 levels in maternal plasma (Figures 3 F-J).

Lastly, we sought to scrutinize how maternal inflammatory response would impact on the early NK cell and IgM immune response in asymptomatic infection (Figures 2 G-I). Curiously, IL-10 inversely associated with NK cell frequency, and no association was found between IL-10 and anti-spike IgM secretion (Figures 3 K, L). Anti-spike IgM levels and NK cell frequency were not associated with either IL-6 or IL-23 (Figures S3 E-H).

Altogether, these data indicate that IL-6 and IL-10 mediate a tug-of-war between asymptomatic viral clearance and transfer of protective anti-RBD IgG to the neonate.

334

Higher concentration of at least one inflammatory cytokine in the cord blood in half of mother:neonate dyads.

337 Even mild maternal immune responses to viral infections have resulted in 338 adverse long-term outcomes associated to fetal inflammatory cytokines exposure 339 (32). Of our 50 mother:neonate dyads, 27 neonates displayed higher 340 concentration of at least one inflammatory cytokine, apart from IL-33 which was 341 not elevated in any of the cord blood samples (Figures 4 A, B). Interestingly, 342 polyfunctional cytokine response appears to be enriched in the cord blood of 343 resolved infections (Figures 4B; 2R), highlighting a possible impact of gestational age in long-term neonatal outcomes. We next evaluated the contribution of 344 345 maternal symptomatology and neonatal sex to the increased inflammatory profile 346 of cord blood. In dyads with cord/maternal ratio higher than 1.5 for at least one 347 cytokine, there was a trend for increased IFN- $\alpha 2$, IL-10, IL-23 and TNF- α in neonates born to symptomatic mothers (Figure 4C). When segregated by 348 neonate's sex, IFN- α 2, IL-10 and TNF- α appear to be enriched in female 349

neonates while IL-8 and IL-18 appear to be increased in male neonates (Figure4D).

SARS-CoV-2 vertical transmission is a rare event occurring in 0-7.7% of 352 353 pregnancies (7, 34, 35). Detection of IgM, and to a lesser extent of IgA, in the 354 cord blood represents an immune fetal response to viral infection and thus is used 355 to document vertical transmission events (9, 27). We detected anti-spike IgA and 356 IgM in one (out of 50) mother: neonate dyads (Figures 4 E-H) in which maternal 357 infection had occurred during the second trimester of gestation, corresponding to a period of higher ACE-2 expression (36). In agreement with the infection 358 359 timeline, maternal blood was negative for anti-spike IgA and IgM antibodies, which ruled out cross-contamination (Figures 4 E-H). Even though we cannot 360 361 ascertain their antigenic specificity, IgD⁻B cells were expanded in this cord blood 362 (Figure 4I), further supporting fetal infection. Moreover, in this dyad all but two cytokines were present at a higher concentration in the cord blood than in the 363 364 mother, conducive of a fetal inflammatory response.

365 All in all, these data underscore that even asymptomatic maternal infections elicit

366 fetal exposure to polyfunctional inflammation, in at least 50% of infections.

367

368

369

370

371

372

373

375 Discussion

376 In this study, we investigated the cellular and molecular underpinnings regulating the balance between maternal SARS-CoV-2 clearance and transplacental 377 378 transfer of protection, over the course of pregnancy. Moreover, we show that while anti-viral cytokine production is short-term, SARS-CoV-2 gestational 379 380 infection leads to high concentration of inflammatory cytokines can be sustained 381 for months. Finally, we describe that even asymptomatic maternal SARS-CoV-2 infection elicits fetal exposure to a polyfunctional inflammation, in a significant 382 383 proportion of neonates.

384 In our cohort of 81 pregnant women ~40% were non-caucasian, affording high 385 robustness to the results obtained as immune responses can differ in distinct 386 population groups due to host genetic factors, differences in the prevalence of 387 comorbidities, and/or differences in the efficiency of transplacental antibody transfer to the fetus (37). We are aware that the vaccinated group is ethnically 388 389 more homogeneous than the SARS-CoV-2⁺ cohort. Even though this disparity is 390 bound to be multifactorial, it mainly reflects socio-economic determinants in the allocation of essential workers - at a time when vaccines were not yet available 391 392 to the general population- and the ethnic diversity of catchment area of the maternity enrolling SARS-CoV-2⁺ participants. In our cohort, 3 neonates tested 393 positive for SARS-CoV-2 by PCR. However, we could not exclude that these 394 395 infections occurred post-nataly, rather than in utero. Indeed, umbilical cord testing 396 for anti-spike IgM, which more accurately identifies in utero infections (27, 38) 397 was negative in all these 3 cases. Distinct from recent studies (7, 8, 36, 39), our 398 SARS-CoV-2⁺ cohort encompassed infections in the second trimester, earlier 399 third trimester and ongoing infections. This allowed us to compare in a gestational

400 age matched manner humoral, cellular and inflammatory immune responses
401 following SARS-CoV-2 infection and COVID-19 vaccination.

Vertical transfer of SARS-CoV-2 antibodies, either in utero or via breastmilk, is 402 403 purported to provide protection to the neonate over the first few months of life (3, 7, 8, 40–44). In SARS-CoV-2 maternal infection, altered glycosylation has been 404 405 proposed to account for impaired transplacental transfer of anti-spike IgG (45). 406 We show that the time window of decreased anti-spike IgG transfer is relatively short (~11 days) and, as previously reported (39), affected more pronouncedly 407 408 IgG transfer to male fetus. Indeed, second and earlier third trimester infections 409 displayed anti-spike IgG transfer ratios of ~1, in the range of what has been observed for other acute viral infections (46-48). Whether this regularization of 410 411 antibody transfer with time elapsed since infection is due to a reversion of anti-412 spike IgG glycosylation patterns (45) once inflammation is subdued, or a result of an extended window for antibody transfer to occur, or a combination of the two 413 414 still needs to be addressed. Consistent with previous works (28-30), we 415 observed that maternal SARS-CoV-2 infection elicited similar NAbs titers to 416 mRNA vaccination. Nonetheless, we noticed a decrease in the frequency of NAbs 417 detection in second trimester infections. This might be due to NAbs waning, to a 418 decrease in NAbs production in the second, and more tolerogenic (32), trimester 419 of pregnancy, or to a combination of the two.

Distinctively from vaccination, SARS-CoV-2 maternal infection led to an almost absence of NAbs in cord blood, independently of gestational age at time of infection. Reduced transplacental transfer NAbs upon maternal SARS-CoV-2 infection had been previously noted (49–51) but the factors that govern it were yet to be identified. We advanced on this by identifying how both maternal

425 inflammation and the nature of the neutralizing antibody response impinges on426 NAbs placental transfer.

To address the role of maternal inflammation on NAbs placental transfer, we 427 428 started by circumventing the limitation of having a very low number of cord blood samples with NAbs (10%) by using anti-RBD IgG as a proxy for NAbs (11–13). 429 430 Our results show that symptomatic infection is associated with reduced 431 transplacental transfer of anti-RBD IgG. Mechanistically, we found that elevated 432 IL-6 was associated with lower anti-RBD IgG transfer, while elevated IL-10 and IL-23 correlated with increased anti-RBD IgG transplacental transfer. IL-6, IL-10 433 434 and IL-23 could affect NAb transfer efficiency by altering NAb glycosylation and or FcRn-NAb binding avidity (9, 52). In contrast to our and others (49-51) 435 436 findings, effective NAbs have been found in the cord blood after maternal SARS-437 CoV-2 infection (30). As the transfer efficiency of anti-RBD IgG relied on infection symptomatology, it is possible that the differences observed were due to distinct 438 439 clinical profiles in the recruited cohorts.

440 Next, we identified how the nature of the neutralizing antibody response would impinge on NAbs placental transfer, as contrary to IgG, IgA and, particularly, IgM 441 442 are not amenable to FcRn-mediated transplacental transfer (10). We found that neutralizing activity was not restricted to IgG isotype. 443 In fact, in resolved infections neutralizing activity correlated exclusively with anti-spike IgM and IgA. 444 445 In contrast, in vaccinated individuals neutralizing activity tended to be solely 446 associated with anti-spike IgG, which might explain the efficient transplacental 447 transfer of NAbs upon vaccination (28–30). Even though this is, to the best of our 448 knowledge, the first report showing the dominance of IgM neutralizing antibodies in maternal SARS-CoV-2 infection, previous reports support our findings. In 449

450 COVID-19 recovered individuals neutralizing activity has been shown to correlate 451 better with anti-spike IgM than with anti-spike IgG (14-16). Furthermore, depleting COVID-19 convalescent plasma from IgM or IgG resulted in a 5.5- and 452 453 4.5-fold decrease in NT50 (17) and purified IgM and IgG fractions displayed 454 similar neutralizing activities in an in vitro neutralization assay (16). Finally, the 455 role of IgM antibodies in SARS-CoV-2 neutralization is also supported by the fact 456 that NAbs with little or no somatic hypermutation potently neutralize the virus, 457 indicating that extensive B cell maturation and isotype switching is not required for NAb development (12, 53). In previous studies, while IgM was a major 458 459 contributor to neutralization, IgG also played an important role including in 460 recovered individuals (14–17). Distinctively, we could only pinpoint a role for IgG 461 neutralizing activity in ongoing, but not in resolved infections. This seemingly 462 more relevant role of IgM for neutralization in maternal infections might be due to the immune alterations subjacent to pregnancy (20), which might have 463 464 evolutionary evolved to balance rapid resolution of maternal infection with vertical 465 transfer of protection to the developing fetus.

466 NK cells and IgM antibodies play a fundamental role in providing fast protective 467 immunity against viral infections, including SARS-CoV-2 (20, 54). We uncovered 468 an early immune response conveyed by anti-spike IgM antibodies and NK cells, which is associated with asymptomatic maternal infection, raising the possibility 469 470 that NK cells might play an important role not only in controlling the development 471 of severe COVID-19 (19), but also in governing the transition from infection to 472 disease. Mechanistically, we unveiled that maternal IL-10 production inversely 473 correlated with NK cell frequency. IL-10 has been reported to promote NK cell antiviral response during acute viral infection (55). Thus, it is possible that the 474

475 decrease in circulating NK cell frequency is the result of IL-10 mediated activation 476 and recruitment to the infection site. When we interpolated our results with clinical data, we remarked that in mothers with ongoing infection, delayed umbilical cord 477 478 clamping led to a selective enrichment of NK cells, but not of B or CD4⁺ T cells, in the cord blood. Remarkably, this enrichment in NK cell transfer to the neonate 479 480 at the time of birth did not occur in recovered infections. Even though the role of 481 maternal transferred immune system in protection the neonate protection against infection remains incompletely understood (56), these data raise the enticing 482 483 possibility that placental NK cell transfer might consist of a maternal sponsored 484 mechanism to protect the neonate, at a time of elevated immune fragility, from 485 post-natal exposure to the infected mother. The physiological relevance of such 486 peri-natal vertical transfer of protection via NK cells might be reinforced by the 487 fact that it has been documented that IgG antibodies that activate NK cells are preferentially transported across the placenta (57). 488

489 Consistent with previous reports (7, 8), we show that upon SARS-CoV-2 490 infection, pregnant women mount an inflammatory response composed by IFN-491 α , IL-6, IL-10, IL-18, IL-33 and MCP-1. Intriguingly, we found that while cytokines 492 related to acute viral response returned to normal levels upon infection clearance. 493 the inflammatory response mediated by IL-6 and IL-18 remained elevated for weeks to months past infection resolution. Sustained inflammatory activation 494 495 after asymptomatic or mild infections might bring some concerns in the future 496 neurological development of the neonate, as maternal inflammation, including by 497 IL-6 and IL-18, have been linked to altered immune responses (58), immune 498 mediated diseases (59), and an increased risk of psychiatric disorders later in life (60, 61). This might be even more worrying, since we observed higher 499

500 concentration of at least one inflammatory cytokine in the cord blood in ~50% of 501 dyads. Ex vivo studies of term placentas indicate that transplacental transfer of 502 most cytokines does not occur (62). However, other studies indicate that maternal 503 inflammatory responses might lead to placental cytokine production (25, 26) and 504 transfer of maternal cytokines has been documented in in vivo animal models 505 (63). Thus, it is possible the cytokines increased by thousand-fold magnitude in 506 the cord blood to be neonatally derived.

507 A combination of uncommon SARS-CoV-2 viraemia in pregnant women (64), and negligible placental co-expression of its canonical cell entry receptors ACE2 and 508 509 TMPRSS2 (65) account for the low frequency of SARS-CoV-2 vertical transmission. As FcRn selectively transports IgG across the placenta, most 510 511 accurate way to identify vertical transmission is through the detection of anti-512 SARS-CoV-2 IgA and IgM antibodies in cord blood. Out of 50 paired mother:neonate dyads, we detected anti-spike IgA and IgM in one cord blood 513 514 sample, which is consistent with previous studies that reported anti-spike IgM in 515 0-7.7% of cord blood samples (7, 34, 66). Curiously, our putative case of vertical transmission occurred during the second trimester, a gestational period when 516 517 ACE2 placental expression peaks (36). Even though maternal infection had long resolved by the time of delivery, the cord blood displayed higher concentration of 518 8 distinct cytokines than the mother. Moreover, this cord blood also exhibited an 519 520 exceptionally high IgD⁻ B cell population documenting a fetal adaptive immune 521 response, likely to SARS-CoV-2 infection.

522 Our data point to an evolutionary trade-off which might benefit the neonate in two 523 ways, first by skewing maternal immune response towards immediate viral 524 clearance, and second by coinciding the optimal vertical transfer of protection,

525 via NK cells and IgA/IgM-NAbs, to the most fragile perinatal period. Considering 526 the energetic costs of mounting an immune response (67), which in vertebrates are equivalent to the ones of reproduction and growth (68), it might be 527 528 advantageous for both the pregnant individual and fetus to concentrate the 529 immune efforts in clearing the infection instead of splitting it between mother and 530 fetus. First, it reasons that by rapidly clearing the viral infection, the maternal 531 immune response effectively prevents it from reaching the developing fetus: 532 second, local immune and placental cells provide potent protective mechanisms that effectively protect the fetus from infection(69-71). Conceivably, the priming 533 534 of IgA- and IgM-NAbs together with NK cells might be best suited to convey immune protection to the neonate soon after birth. Pertinently, IgA- and IgM-535 536 NAbs producing plasma cells primed during pregnancy are known to migrate to 537 the breast and secrete protective IgA- and IgM-NAbs to the milk (1, 3, 40, 72). We showed that NK cells are selectively transferred perinatally in ongoing 538 539 maternal infections. Thus, gestational IgM and NK cell priming and perinatal 540 transfer might consist in a seemingly maternal sponsored mechanism of 541 protection to the neonate, at a time when there is an increased risk of horizontal 542 viral transmission, due to close contact with the mother, and higher fragility of the 543 newborn, being exposed for the first time to the outside environment without the 544 placental protective barrier.

- 545
- 546
- 547
- 548
- 549

550 Methods

551 Biospecimen collection

A total of 79 peripheral and 69 cord blood samples were collected at the time of 552 553 delivery from 60 SARS-CoV-2 infected pregnant women, 12 non-infected pregnant controls, and 9 from COVID-19 mRNA vaccinated pregnant women. 554 555 SARS-CoV-2 positive and negative participants were recruited between May 556 2020 and February 2021, before vaccination had become available to the general population. Vaccinated participants were recruited between July 2021 and 557 558 February 2022. Nasopharyngeal swabs were obtained for all study participants 559 upon hospital admission. Nasopharyngeal swabs of the babies were collected 560 whenever possible. All women underwent clinical evaluation of vital signs and 561 symptoms, laboratory analysis and radiological chest assessment at the 562 discretion of physicians. Therapeutic management was consequently tailored according to clinical findings and national guidelines. Demographic and clinical 563 564 characteristics are detailed in Tables 1, 2 and 3. Cord blood was obtained through 565 venipuncture of the cord vein. Blood samples were immediately processed.

566

567 Exclusion criteria

In total, we recruited 63 pregnant women suspected of SARS-CoV-2 infection.
Three participants were excluded from the study due to loss of biospecimens'
integrity. One participant was excluded from the control group due to prior
exposure to SARS-CoV-2.

572

573 Peripheral and cord blood mononuclear cells (PBMCs and CBMCs) 574 isolation

Peripheral and cord blood samples were collected in EDTA tubes. PBMCs and
CBMCs were isolated by density gradient centrifugation (Biocoll, Merck Millipore)
(3, 73), cryopreserved in 10% DMSO in FBS and stored at -80°C until subsequent
analysis. Plasma samples were carefully removed from the cellular fraction and
stored at -80°C, until further analysis.

580

581 ELISA

Antibody binding to SARS-CoV-2 trimeric spike protein or its RBD domain was 582 assessed by a previously described in-house ELISA assay (74) based on the 583 584 protocol by Stadlbauer et al (75). Briefly, 96-well plates (Nunc) were coated overnight at 4°C with 0.5 mg/ml of trimeric spike or RBD. After blocking with 3% 585 586 BSA diluted in 0.05% PBS-T, 1:50 diluted plasma was added and incubated for 587 1 h at room temperature. Plates were washed and incubated for 30 min at room temperature with 1:25,000 dilution in 1% BSA 0.05% PBS-T of HRP-conjugated 588 589 anti-human IgA, IgG and IgM antibodies (Abcam, ab97225/ab97215/ab97205). 590 Plates were washed and incubated with TMB substrate (BioLegend), stopped by 591 adding phosphoric acid (Sigma) and read at 450nm. Cut-off for plasma samples 592 resulted from the mean of OD₄₅₀ values from negative controls plus 3 times the standard deviation (74). Endpoint titers were established using a 3-fold dilution 593 series starting at 1:50 and ending at 1:109,350 and defined as the last dilution 594 595 before the signal dropped below OD₄₅₀ of 0.15. This value was established using 596 plasma from pre-pandemic samples collected from subjects not exposed to 597 SARS-CoV-2 (74). For samples that exceeded an OD₄₅₀ of 0.15 at last dilution (1:109,350), end-point titter was determined by interpolation (76). As previously 598 described (74), in each assay we used 6 internal calibrators from 2 high-, 2 599

medium- and 2 low-antibody producers that had been diagnosed for COVID-19
through RT-PCR of nasopharyngeal and/or oropharyngeal swabs. As negative
controls, we used pre-pandemic plasma samples collected prior to July 2019.

603

604 **Production of ACE2 expressing 293T cells**

605 Production of 293T cells stably expressing human ACE2 receptor was done as 606 previously described (77). Briefly, for production of VSV-G pseudotyped lentiviruses encoding human ACE2, 293T cells were transfected with pVSV-G, 607 608 psPAX2 and pLEX-ACE2 using jetPRIME (Polyplus), according to 609 manufacturer's instructions. Lentiviral particles in the supernatant were collected 610 after 3 days and were used to transduce 293T cells. Three days after 611 transduction, puromycin (Merck, 540411) was added to the medium, to a final 612 concentration of 2.5 µg/ml, to select for infected cells. Puromycin selection was maintained until all cells in the control plate died and then reduced to half. The 613 614 293T-Ace2 cell line was passaged six times before use and kept in culture 615 medium supplemented with 1.25 µg/ml puromycin.

616

617 Production of spike pseudotyped lentivirus

To generate spike pseudotyped lentiviral particles, 6x10⁶ 293ET cells were co-618 transfected with 8.89 mg pLex-GFP reporter, 6.67 mg psPAX2, and 4.44 mg 619 620 pCAGGS-SARS-CoV-2-Strunc D614G, using jetPRIME according to 621 manufacturer's instructions. The virus-containing supernatant was collected after 3 days, concentrated 10 to 20-fold using Lenti-XTM Concentrator (Takara, 622 623 631231), aliquoted and stored at -80°C. Pseudovirus stocks were titrated by serial 624 dilution and transduction of 293T-Ace2 cells. At 24h post transduction, the

625 percentage of GFP positive cells was determined by flow cytometry, and the 626 number of transduction units per mL was calculated.

627

628 Neutralization assay

Heat-inactivated plasma was four-fold serially diluted and then incubated with spike pseudotyped lentiviral particles for 1h at 37°C. The mix was added to a preseeded plate of 293T-Ace2 cells, with a final MOI of 0.2. At 48h post-transduction, the fluorescent signal was measured using the GloMax Explorer System (Promega). The relative fluorescence units were normalized to those derived from the virus control wells (cells infected in the absence of plasma), after subtraction of the background in the control groups with cells only.

636

637 Immune phenotyping of maternal and cord blood leukocytes

For immunophenotyping of B, T and NK cells, cryopreserved PBMCs and CBMCs 638 639 were rested for 1h at 37°C and stained with a fixable viability dye eFluor[™] 506 640 (Invitrogen) and surface labelled with the following antibodies all from BioLegend: anti-CD3 (300424/UCHT1), anti-CD4 (344666/SK3), anti-CD69 (310910/FN50), 641 642 anti-CXCR5 (356904/J252D4), anti-CCR6 (353432/G034E3), anti-CD19 (363026/SJ25C1), anti-IgD (348250/IA6-2), and anti-CD56 (318348/HCD56). 643 Cells were washed, fixed with 1% PFA and acquired in BD FACS Aria III (BD 644 645 Biosciences) and analyzed with FlowJo v10.7.3 software (Tree Star).

646

647 Luminex

Plasma samples were thawed and tested in the 13-plex LegendPlex Human Inflammation panel 1 (BioLegend, 740809) to quantify levels of IL-1β, IFN- α 2,

650 IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23 and IL-33. 651 The assay was performed according to manufactor's instructions and was 652 modified by using half of the amount of all reagents. All plasma samples were 653 diluted 2X with assay buffer, and sample concentrations were calculated 654 according to the dilution factor. Briefly, 12.5 µl of diluted plasma or standard, and 655 12.5 µl of mixed beads were added to each well and incubated for 2 hours. The 656 plate (V-bottom 96 well plate) was washed twice with 100 µl of wash buffer. 657 Samples and standards were incubated with 12.5 µl of detection antibody for 1 658 hour followed by an incubation of 30 minutes with 12.5 µl of Streptavidin-PE. The 659 plate was washed once, and samples were resuspended in 75 µl of wash buffer. 660 All incubation steps were performed at 800 rpm at room temperature and 661 protected from the light. Samples were acquired in a BD FACS Canto (BD 662 Biosciences) and analyzed with the Windows LegendPlex software (v8.0 663 BioLegend).

664

665 Statistical Analysis

Statistical analysis was performed by using GraphPad Prism v9.00. First, we 666 667 tested the normality of the data by using D'Agostino & Pearson normality test, by 668 checking skewness and kurtosis values and visual inspection of data. Then, if the 669 samples followed a normal distribution, we chose the appropriate parametric test; 670 otherwise, the non-parametric counterpart was chosen. In two groups comparison: for paired data the Wilcoxon matched-pairs signed-rank test and 671 672 paired t test were used; for unpaired data, Man-Whitney test and the unpaired t 673 test were used. For multiple groups comparison, ordinary one-way analysis of variance (ANOVA) with posttest Holm-Sidàk's multiple comparisons or Kruskal-674

Wallis tests with posttest Dunn's multiple comparisons were used as indicated in 675 676 figure legends. Spearman and Pearson correlation tests were used in correlation analysis as described. The ratios of cord/maternal ratio for inflammatory 677 cytokines were imported into an excel spreadsheet and analyzed in R 678 (v2022.2.3.0) to generate matrices with ggplot package. Polar plots were 679 680 generated in Origin 2022. The half-maximal neutralization titer (NT50), defined 681 as the reciprocal of the dilution at which infection was decreased by 50%, was determined using four-parameter nonlinear regression (least-squares regression 682 683 without weighting; constraints: bottom = 0). To measure the magnitude of the 684 difference, the effect size was calculated as described (78, 79)-for Paired t test: 685 Cohen's d (d) is small if <0.3, medium if \geq 0.3 or large if \geq 0.8;

-for Wilcoxon test and Man-Whitney test: correlation coefficient r (r) is small if 687 <0.3, medium if ≥ 0.3 or large if ≥ 0.5 ;

688 -for Kruskal-Wallis and ordinary one-way ANOVA: eta square (η²) is small if 689 <0.01, medium if ≥0.06 or large if ≥0.14.

Effect sizes values are reported in figure legends and are labeled as + for small,
⁺⁺ for medium and ⁺⁺⁺ for large.

692

693 Study Approval

All participants provided informed consent and all procedures were approved by the ethics committees of Centro Hospitalar de Lisboa Central (859/2020) and of NOVA Medical School (112/2021/CEFCM), in accordance with the provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonization.

699

700 Author contributions

J.G., M.M., M.A., and J. C.-N. designed and performed experiments and analyzed the data. N.C., F.S., J.G., and H.S. enrolled the subjects and collected demographic data. M.J.A., C.A., and C.P. provided critical expertise. H.S. conceptualized the study, designed experiments, analyzed the data, supervised the project, and wrote the manuscript. All authors discussed the results and commented on the manuscript.

707

708 Acknowledgements

709 We are very grateful to all study participants and to all the CHULC doctors and nurses that contributed to this study. We thank Cláudia Andrade (Flow Cytometry 710 711 Platform), Daniela Amaral-Silva, Manuela Correia, Ricardo Santos and 712 Margarida Archer for support. This work was funded by European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and by Gilead Génese 713 714 (PGG/009/2017) grants to H.S., RESEARCH4COVID 19 (Ref 580) to M.J.A. 715 M.J.A., H.S. and J.G are supported by FCT through work contracts 716 CEECIND/02373/2020, CEECIND/01049/2020 and PTDC/MEC-717 REU/29520/2017, respectively. Graphical abstract created using was 718 BioRender.com.

719

- 720
- 721
- 722

723

724

725 **References**

- Laouar A. Maternal Leukocytes and Infant Immune Programming during
 Breastfeeding. *Trends in Immunology* 2020;41(3):225–239.
- 728 2. Atyeo C, Alter G. The multifaceted roles of breast milk antibodies. *Cell*729 2021;184(6):1486–1499.
- 3. Gonçalves J et al. Secretory IgA and T cells targeting SARS-CoV-2 spike
- protein are transferred to the breastmilk upon mRNA vaccination. *Cell Reports Medicine* 2021;2(12):1-10.
- 4. Delahoy MJ et al. Characteristics and Maternal and Birth Outcomes of
- 734 Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 COVID-
- 735 NET, 13 States, March 1–August 22, 2020. MMWR. Morbidity and Mortality
- 736 Weekly Report 2020;69(38):1347–1354.
- 5. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal Screening for SARS-CoV-
- 738 2 in Women Admitted for Delivery. New England Journal of Medicine
 739 2020;382(22):2163–2164.
- 6. Lokken EM et al. Clinical characteristics of 46 pregnant women with a severe
- 741 acute respiratory syndrome coronavirus 2 infection in Washington State.
- American Journal of Obstetrics and Gynecology 2020;223(6):911.e1-911.e14.
- 743 7. Garcia-Flores V et al. Maternal-fetal immune responses in pregnant women
 744 infected with SARS-CoV-2. *Nature Communications* 2022;13(1):1–20.
- 8. Gee S et al. The legacy of maternal SARS-CoV-2 infection on the immunology
 of the neonate. *Nature Immunology* 2021;22(12):1490–1502.
- 9. Wilcox CR, Holder B, Jones CE. Factors affecting the FcRn-mediated
 transplacental transfer of antibodies and implications for vaccination in
 pregnancy. *Frontiers in Immunology* 2017;8:1–13.

- 10. Albrecht M, Arck PC. Vertically Transferred Immunity in Neonates: Mothers,
- 751 Mechanisms and Mediators. *Frontiers in Immunology* 2020;11:1-14.
- 11. Shi R et al. A human neutralizing antibody targets the receptor-binding site of
- 753 SARS-CoV-2. Nature 2020;584(7819):120–124.
- 12. Brouwer PJM et al. Potent neutralizing antibodies from COVID-19 patients
- define multiple targets of vulnerability. *Science (1979)* 2020;369:6431–650.
- 13. Wu Y et al. A noncompeting pair of human neutralizing antibodies block
- 757 COVID-19 virus binding to its receptor ACE2. Science (1979) 2020;368:1274-
- 758 1278.
- 14. Harrington WE et al. Rapid decline of neutralizing antibodies is associated
- with decay of IgM in adults recovered from mild COVID-19. *Cell Reports Medicine*2021;2(4):1-9.
- 762 15. Anand SP et al. Longitudinal analysis of humoral immunity against SARS-
- 763 CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset.
- 764 *Cell Reports Medicine* 2021;2(6):1-10.
- 16. Klingler Jã et al. Role of Immunoglobulin M and A Antibodies in the
 Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2. *Journal of Infectious Diseases* 2021;223(6):957–970.
- 768 17. Gasser R et al. Major role of IgM in the neutralizing activity of convalescent
 769 plasma against SARS-CoV-2. *Cell Reports* 2021;34(9):1-5.
- 18. Grifoni A et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in
 Humans with COVID-19 Disease and Unexposed Individuals. *Cell*2020;181(7):1489-1501.
- 773 19. Witkowski M et al. Untimely TGFβ responses in COVID-19 limit antiviral
 774 functions of NK cells. *Nature* 2021;600(7888):295–301.

- 20. Abu-Raya B, Michalski C, Sadarangani M, Lavoie PM. Maternal
 Immunological Adaptation During Normal Pregnancy. *Frontiers in Immunology*2020;11:1-18.
- 21. Lee Y-C, Lin S-J. Neonatal natural killer cell function: Relevance to antiviral
- immune defense. *Clinical and Developmental Immunology* 2013;2013:1–6.
- 780 22. Galbraith MD et al. Specialized interferon action in COVID-19. *PNAS*781 2022;119(11):1–12.
- 23. Lu L, Zhang H, Dauphars DJ, He YW. A Potential Role of Interleukin 10 in
- 783 COVID-19 Pathogenesis. *Trends in Immunology* 2021;42(1):3–5.
- 24. del Valle DM et al. An inflammatory cytokine signature predicts COVID-19
- 785 severity and survival. *Nature Medicine* 2020;26(10):1636–1643.
- 786 25. Bunders MJ et al. Fetal exposure to HIV-1 alters chemokine receptor
- expression by CD4+T cells and increases susceptibility to HIV-1. *Scientific Reports* 2014;4:1-8.
- 789 26. Hong M et al. Trained immunity in newborn infants of HBV-infected mothers.
- 790 *Nature Communications* 2015;6:1-12.
- 791 27. Haider SA. Serum IgM in Diagnosis of Infection in the Newborn. Archives of
- 792 Disease in Childhood 1972;47: 382-393.
- 28. Collier ARY et al. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant
- and Lactating Women. JAMA Journal of the American Medical Association
 2021;325(23):2370–2380.
- 796 29. Gray KJ et al. Coronavirus disease 2019 vaccine response in pregnant and
- 797 lactating women: a cohort study. American Journal of Obstetrics and Gynecology
- 798 2021;225(3):303.e1-303.e17.

- 30. Matsui Y et al. Neutralizing antibody activity against SARS-CoV-2 variants in
- 800 gestational age-matched mother-infant dyads after infection or vaccination. JCI
- 801 *Insight* 2022;7(12):1-15.
- 802 31. Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and
 803 Diseases. *Immunity* 2019;50(5):1132–1148.
- 32. Yockey LJ, Iwasaki A. Interferons and Proinflammatory Cytokines in
 Pregnancy and Fetal Development. *Immunity* 2018;49(3):397–412.
- 33. Törnblom SA et al. mRNA expression and localization of bNOS, eNOS and
- iNOS in human cervix at preterm and term labour. *Reproductive Biology and Endocrinology* 2005;3(33):1–9.
- 809 34. Kotlyar AM et al. Vertical transmission of coronavirus disease 2019: a
- 810 systematic review and meta-analysis. American Journal of Obstetrics and
- 811 *Gynecology* 2021;224(1):35-53.e3.
- 35. Norman M et al. Association of Maternal SARS-CoV-2 Infection in Pregnancy
- 813 with Neonatal Outcomes. JAMA Journal of the American Medical Association
- 814 2021;325(20):2076–2086.
- 36. Lu-Culligan A et al. Maternal respiratory SARS-CoV-2 infection in pregnancy
- is associated with a robust inflammatory response at the maternal-fetal interface.
- 817 *Med* 2021;2(5):591–610.
- 818 37. Nunes MC, Madhi SA. COVID-19 vaccines in pregnancy. *Trends in Molecular*819 *Medicine* 2022;28(8):662-680.
- 38. Male V. SARS-CoV-2 infection and COVID-19 vaccination in pregnancy.
- 821 *Nature Reviews Immunology* 2022;22(5):277–282.
- 39. Bordt EA et al. Maternal SARS-CoV-2 infection elicits sexually dimorphic
- 823 placental immune responses. *Sci. Transl. Med* 2021;13:2–15.

40. Fox A et al. Robust and Specific Secretory IgA Against SARS-CoV-2
Detected in Human Milk. *iScience* 2020;23(11):1-8.

41. Flannery DD et al. Assessment of Maternal and Neonatal Cord Blood SARS-

- 827 CoV-2 Antibodies and Placental Transfer Ratios. *JAMA Pediatrics* 828 2021;175(6):594–600.
- 42. Bwire GM, Njiro BJ, Mwakawanga DL, Sabas D, Sunguya BF. Possible
- 830 vertical transmission and antibodies against SARS-CoV-2 among infants born to
- 831 mothers with COVID-19: A living systematic review. *Journal of Medical Virology*
- 832 2021;93(3):1361–1369.
- 43. Poon LC et al. Relationship between viral load, infection-to-delivery interval

and mother-to-child transfer of anti-SARS-CoV-2 antibodies. Ultrasound in

835 *Obstetrics and Gynecology* 2021;57(6):974–978.

- 44. Shook LL et al. Durability of Anti-Spike Antibodies in Infants After Maternal
 COVID-19 Vaccination or Natural Infection. *JAMA Journal of the American*
- 838 Medical Association 2022;327(11):1087–1089.
- 45. Atyeo C et al. Compromised SARS-CoV-2-specific placental antibody
 transfer. *Cell* 2021;184(3):628-642.
- 46. Castanha PMS et al. Perinatal analyses of Zika- and dengue virus-specific
 neutralizing antibodies: A microcephaly case-control study in an area of high
 dengue endemicity in Brazil. *PLoS Neglected Tropical Diseases* 2018;13(3):1-
- 844 17.
- 47. Perret C et al. Dengue infection during pregnancy and transplacental antibody
- transfer in Thai mothers. *Journal of Infection* 2005;51(4):287–293.

48. Fu C et al. Placental antibody transfer efficiency and maternal levels: Specific
for measles, coxsackievirus A16, enterovirus 71, poliomyelitis I-III and HIV-1
antibodies. *Scientific Reports* 2016;6:1-6.

49. Sherer ML et al. Dysregulated immunity in SARS-CoV-2 infected pregnant
women. [preprint]. doi:10.1101/2020.11.13.20231373. Posted on medRxiv
November 16, 2020.

50. Govindaraj S et al. Compromised SARS-CoV-2 neutralizing antibody
response in cord blood versus mothers. *Topics in Antiviral Medicine*2021;29(1):223–223.

51. Joseph NT et al. Maternal Antibody Response, Neutralizing Potency, and
Placental Antibody Transfer After Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) Infection. *Obstet Gynecol* 2021;138(2):189–197.

52. Abu-Raya B, Smolen KK, Willems F, Kollmann TR, Marchant A. Transfer of
maternal antimicrobial immunity to HIV-exposed uninfected newborns. *Frontiers in Immunology* 2016;7:1–10.

53. Kreer C et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-

Neutralizing Antibodies from COVID-19 Patients. *Cell* 2020;182(4):843-854.

54. Shmeleva E v., Colucci F. Maternal natural killer cells at the intersection
between reproduction and mucosal immunity. *Mucosal Immunology*2021;14(5):991–1005.

55. Stacey MA, Marsden M, Wang ECY, Wilkinson GWG, Humphreys IR. IL-10
Restricts Activation-Induced Death of NK Cells during Acute Murine
Cytomegalovirus Infection. *The Journal of Immunology* 2011;187(6):2944–2952.
56. Langel SN, Blasi M, Permar SR. Maternal immune protection against
infectious diseases. *Cell Host and Microbe* 2022;30(5):660–674.

57. Jennewein MF et al. Fc Glycan-Mediated Regulation of Placental Antibody

- 873 Transfer. *Cell* 2019;178(1):202-215.
- 58. Gleditsch DD et al. Maternal inflammation modulates infant immune response
- patterns to viral lung challenge in a murine model. *Pediatric Research*2014;76(1):33–40.
- 59. Apostol AC, Jensen KDC, Beaudin AE. Training the Fetal Immune System
- Through Maternal Inflammation—A Layered Hygiene Hypothesis. *Frontiers in Immunology* 2020;11:1-14.
- 60. al-Haddad BJS et al. The fetal origins of mental illness. *American Journal of*Obstetrics and Gynecology 2019;221(6):549–562.
- 882 61. Vigneswaran R, Aitchison SJ, Mcdonald HM, Khong Y, Hiller JE. Cerebral
 883 palsy and placental infection: a case-cohort study. *BMC Pregnancy and*884 *Childbirth* 2004;4:1-7.
- 62. Aaltonen R, Heikkinen T, Hakala K, Laine K, Alanen A. *Transfer of Proinflammatory Cytokines Across Term Placenta*. Obstetrics & Gynecology
 2005;106(4):802-807.
- 888 63. Dahlgren J, Samuelsson AM, Jansson T, Holmäng A. Interleukin-6 in the
 889 maternal circulation reaches the rat fetus in mid-gestation. *Pediatric Research*890 2006;60(2):147–151.
- 64. Edlow AG et al. Assessment of Maternal and Neonatal SARS-CoV-2 Viral
 Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies
 During the COVID-19 Pandemic. *JAMA Netw Open* 2020;3(12):1-17.
- 894 65. Pique-Regi R et al. Does the human placenta express the canonical cell entry
 895 mediators for sars-cov-2?. *Elife* 2020;9:1–15.
- 66. Beharier O et al. Efficient maternal to neonatal transfer of antibodies against
 SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. *Journal of Clinical Investigation* 2021;131(13):1-9.
- 899 67. Sheldon BC, Verhulst S. Ecological immunology: costly parasite defences
 900 and trade-offs in evolutionary ecology. *Trends in Ecology & Evolution*901 1996;11(8):317–321.
- 902 68. Lochmiller RL, Deerenberg C. Trade-offs in evolutionary immunology: just 903 what is the cost of immunity?. *Oikos* 2000;88:87–98.
- 904 69. Crespo ÂC, Strominger JL, Tilburgs T. Expression of KIR2DS1 by decidual
- 905 natural killer cells increases their ability to control placental HCMV infection.
- 906 PNAS 2016;113(52):15072–15077.
- 907 70. Coyne CB, Lazear HM. Zika virus-reigniting the TORCH. *Nature Reviews*908 *Microbiology* 2016;14(11):707–715.
- 909 71. Stegmann BJ, Carey JC. TORCH Infections. Toxoplasmosis, Other (syphilis,
- 910 varicella-zoster, parvovirus B19), Rubella, Cytomegalovirus (CMV), and Herpes
- 911 infections. *Curr Womens Health Rep* 2002;2(4):253–258.
- 912 72. Pace RM et al. Characterization of SARS-CoV-2 RNA, Antibodies, and
 913 Neutralizing Capacity in Milk Produced by Women with COVID-19. *mBio*914 2021;12(1):1–11.
- 915 73. Amaral-Silva D et al. Direct tissue-sensing reprograms TLR4+ Tfh-like cells
 916 inflammatory profile in the joints of rheumatoid arthritis patients. *Communications*917 *Biology* 2021;4(1):1–16.
- 918 74. Gonçalves J et al. Evaluating SARS-CoV-2 Seroconversion Following
 919 Relieve of Confinement Measures. *Frontiers in Medicine* 2020;7:1–10.

- 920 75. Stadlbauer D et al. SARS-CoV-2 Seroconversion in Humans: A Detailed
- 921 Protocol for a Serological Assay, Antigen Production, and Test Setup. Current
- 922 *Protocols in Microbiology* 2020;57(1):1–15.
- 923 76. Stadlbauer D et al. Repeated cross-sectional sero-monitoring of SARS-CoV-
- 924 2 in New York City. *Nature* 2021;590(7844):146–150.
- 925 77. Alenquer M et al. Signatures in SARS-CoV-2 spike protein conferring escape
- 926 to neutralizing antibodies. *PLoS Pathogens* 2021;17(8):1–25.
- 927 78. Tomczak M, Tomczak E. The need to report effect size estimates revisited.
- 928 An overview of some recommended measures of effect size. TRENDS in Sport
- 929 Sciences 2014;1(21):19–25.
- 930 79. Cohen J. Statistical Power Analysis for the Behavioral Sciences Second931 Edition. 1988.
- 932
- 933
- 934
- 935
- 936
- 937
- 938
- 939
- 940
- 941
- 942
- 943
- 944

945 Figure legends

- 946 Figure 1- Low NAbs in neonates are associated with maternal production
- of IgM-NAbs and impaired transfer of IgG-NAbs in symptomatic infections. 947
- 948 A- Outline of participants recruitment, divided in CoV-2⁻ group of pregnant women
- negative for SARS-CoV-2 (n = 12); in 2R group (recovered at delivery) of 949
- 950 pregnant women that tested positive for SARS-CoV-2 in the second trimester (n
- = 9); in 3R group (recovered at delivery) of pregnant women that tested positive 951
- for SARS-CoV-2 earlier in the third trimester (n = 11); 30 group (ongoing infection 952
- 953 at delivery) of pregnant women that tested positive for SARS-CoV-2 at the time
- 954 of delivery (n = 38); Vac group includes pregnant women that were vaccinated
- with COVID-19 BNT162b2 vaccine (n = 9). 955
- 956 B- Paired dyad analysis of anti-spike (left) and anti-RBD (right) IgG in 2R, 3R and
- 957 30 groups. Dashed line indicates assay cutoff (n = 50 dyads).
- C- Paired dyad endpoint titers for anti-spike (left) and anti-RBD (right) IgG in 2R, 958
- 959 3R and 3O groups (n = 50 dyads).
- 960 D-Anti-spike (left) and anti-RBD (right) IgG transfer ratio in 2R, 3R and 3O groups 961 (n = 39).
- 962 E- Correlation between anti-spike (left) and anti-RBD (right) IgG transfer ratio and elapsed time between diagnosis and delivery (n = 39). 963
- F- Paired dyad analysis of anti-spike IgG levels in 2R+3R and 3O groups 964 965 according to neonate sex (2R+3R n = 15 dyads; 3O n = 18 dyads).
- 966 G- Neutralization curves of maternal plasma from SARS-CoV-2 positive (CoV-2+,
- 967 n = 50) and vaccinated (Vac, n = 6) participants.
- 968 H- Neutralization curves of cord plasma from SARS-CoV-2 positive (CoV-2⁺, n =
- 50) and vaccinated (Vac, n = 6) participants. 969

- 970 I- Neutralization titer (NT50) of maternal plasma from SARS-CoV-2 positive
- 971 individuals from 2R, 3R and 3O groups; nd: not detectable (n = 50).
- 972 J- NT50 paired dyad analysis in SARS-CoV-2 positive (CoV-2⁺, n = 50) and
- 973 vaccinated participants (Vac, n= 6).
- 974 K- Anti-spike (left) and anti-RBD (right) IgG transfer ratio in 3O group in function
- of the presence (Sym) or absence (Asym) of symptoms (n = 24).
- 976 L- Correlation between maternal neutralization titers (NT50) and anti-spike IgG
- 977 (left) or anti-spike IgM (right) in 3O group (n = 35).
- 978 M- Correlation between maternal anti-spike IgM and IgG levels in 3O group (n =979 35).
- 980 N- Maternal NT50 in function of the presence of anti-spike IgG and/or IgM 981 antibodies in 3O group (n = 35).
- 982 O- Correlation between maternal neutralization titers (NT50) and anti-spike IgG
- 983 (left) or anti-spike IgM (right) in 2R+3R groups (n = 15).
- 984 P- Correlation between maternal anti-spike IgM and IgG levels in 2R+3R groups985 (n = 15).
- 986 Q- Maternal NT50 in function of the presence of anti-spike IgG and/or IgM 987 antibodies in 2R+3R groups (n = 15)
- 988 R- Correlation between maternal NT50 and anti-spike IgG (orange), IgA (green)
- 989 and IgM (purple) in vaccinated group (n = 6).
- 990 nd: not detectable; p values *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns,
- 991 not significant were determined by parametric paired t test (B, C, F, J), non-
- 992 parametric paired Wilcoxon test (B, C, J), unpaired t test (K), Mann-Whitney test
- 993 (J, K, Q), ordinary ANOVA, post hoc Holm-Sidak (D), Kruskal-Wallis test, post
- hoc Dunn's (I, N), Pearson correlation (E, O) and Spearman correlation (L, M, P,

995	R). Effect size measures ***high, **medium, *small were determined by d =
996	Cohen's d (B, C, F, J, K), r = correlation coefficient r (B, C, J, I, K, M, Q) and η^2 =
997	eta-squared (D, I, N).

- 998
- 999 Figure 2- Asymptomatic maternal infection is associated with increased
- 1000 early immune response comprised by anti-spike IgM and NK cells.
- 1001 A- Maternal B cell frequency from 3O group in function of the presence (Sym) or
- 1002 absence (Asym) of symptoms (n = 23).
- 1003 B- Frequency of IgD⁻ B cells as in A.
- 1004 C- Frequency of CD4⁺ T cells as in A.
- 1005 D- Frequency of CD69⁺CD4⁺ T cells as in A.
- 1006 E- Frequency of CCR6⁺CD4⁺ T cell as in A.
- 1007 F- Frequency of CXCR5⁺CD4⁺ T cell as in A.

1008 G- Maternal NK cell frequency in participants diagnosed for SARS-CoV-2 within

- 1009 7 days of delivery in asymptomatic (Asym) and symptomatic (Sym) individuals (n
- 1010 = 17).
- 1011 H- Cord blood NK cell frequency from participants diagnosed for SARS-CoV-2
- 1012 within 7 days of delivery, in function of the presence (Sym) or absence (Asym) of
- 1013 symptoms (n = 17).
- 1014 I- Maternal anti-spike IgM levels as in G.
- 1015 J- Cord blood NK cell frequency upon either immediate or delayed umbilical cord
- 1016 clamping, in 3O group (n = 21).
- 1017 K- Cord blood B cell frequency as in J.
- 1018 L- Cord blood CD4⁺ T cell frequency J.

- 1019 M- Cord blood NK cell frequency upon either immediate or delayed umbilical cord
- 1020 clamping, in 2R+3R group (n = 10).
- 1021 p values *p < 0.05; ns, not significant were determined by unpaired t test (A, B,
- 1022 C, F, H J, K, L), Mann-Whitney test (D, E, G, M). Effect size measures ⁺⁺⁺high,
- ⁺⁺medium, ⁺small were determined by d = Cohen's d (A, B, C, F, H, J, K, L), r =
- 1024 correlation coefficient r (D, E, G, M).

1025

1026 Figure 3- Maternal inflammatory response balances antibody placental

1027 transfer with NK cell expansion.

- 1028 A- Maternal plasma concentration (ng/mL) of IFN-α2, IFN-γ, IL-17A, IL-1β, IL-33,
- 1029 IL-6, TNF-α, IL-18, IL-10, IL-12p70, IL-23, IL-10 and MCP-1 in recovered (2R+3R,
- 1030 n = 20) and ongoing (3O, n = 38) infections.
- 1031 B- Correlation between maternal concentration of IFN-α2, MCP-1, IL-6, IL-18 and
- 1032 elapsed time between diagnosis and delivery (n = 58).
- 1033 C- Correlation between anti-RBD IgG transfer ratio and IL-6 concentration in 1034 maternal plasma (n = 39).
- 1035 D- Correlation between anti-RBD IgG transfer ratio and IL-10 concentration in
- 1036 maternal plasma in the 3O group (n = 24).
- 1037 E- Correlation between anti-RBD IgG transfer ratio and IL-23 concentration in
- 1038 maternal plasma in the 3O group (n = 24).
- F- Correlation between anti-RBD IgG levels and IL-6 concentration in maternalplasma (n = 48).
- 1041 G- Correlation between anti-RBD IgG levels and IL-10 concentration in maternal
- 1042 plasma in the 3O group (n = 28).

1043 H- Correlation between anti-RBD IgG levels and IL-23 concentration in maternal

1044 plasma in the 3O group (n = 28).

1045 I- Correlation between NT50 and IL-6 (left) or IL-10 (right) concentration in

1046 maternal plasma in the 3O group (n = 19).

- 1047 J- Correlation between NT50 and IL-23 concentration in maternal plasma in the
- 1048 3O group (n = 19).
- 1049 K- Correlation between anti-spike IgM levels and IL-10 concentration in maternal

1050 plasma within 7 days between diagnosis and delivery (n = 17).

- 1051 L- Correlation between IL-10 concentration and NK cell frequency in 3O group (n1052 = 36).
- 1053 p values *p < 0.05; ns, not significant were determined by Mann-Whitney test (A),

1054 Spearman correlation (B, F, I, K, L) and Pearson correlation (C, D, E, G, H). Effect

size measures +++high, ++medium, +small were determined by r = correlation
coefficient r (A).

1057

Figure 4- Higher concentration of at least one inflammatory cytokine in the
 cord blood in half of mother:neonate dyads.

- 1060 A- Plasma concentration (ng/mL) of IFN-α2, IFN-γ, IL-17A, IL-1β, IL-33, IL-6,
- 1061 TNF- α , IL-18, IL-10, IL-12p70, IL-23, IL-10 and MCP-1 in paired mother: neonate

1062 dyads (n = 50 dyads).

- 1063 B- Cytokine ratio between cord and maternal blood (n=27 dyads).
- 1064 C- Polar plots depicting the cytokine profile of neonates born to asymptomatic 1065 (left) and symptomatic (right) mothers, in dyads with cord/maternal ratio>1.5
- 1066 (n=27 dyads).

- 1067 D- Polar plots depicting the cytokine profile of female (left) and male (right)
- neonates, in dyads with cord/maternal ratio>1.5 (n=27 dyads).
- 1069 E- Paired dyad analysis of anti-spike IgA levels. Dashed line indicates assay
- 1070 cutoff (n = 50 dyads).
- 1071 F- Paired dyad analysis of anti-spike IgM levels. Dashed line indicated assay
- 1072 cutoff (n = 50 dyads).
- 1073 G- Endpoint titers for anti-spike IgA measured in paired dyads; nd: not detectable1074 (n = 50 dyads).
- H- Endpoint titers for anti-spike IgM measured in paired dyads; nd: not detectable(n = 50 dyads).
- 1077 I- Frequency of IgD⁻ B cells in paired dyads in 2R, 3R and 3O groups (n=30
 1078 dyads).
- 1079 J- Cytokine ratio between cord and maternal blood.
- 1080 p values *p < 0.05, ***p <0.001, ****p < 0.0001; ns, not significant were 1081 determined by non-parametric paired Wilcoxon test (A, E, F, I) and parametric 1082 paired t test (I). Effect size measures ***high, **medium, *small were determined 1083 by r = correlation coefficient r (A, E, F, I) and d = Cohen's d (I).
- 1084

1085 Figure S1- Antibody levels in maternal:neonate dyads classified by sex of 1086 the neonate and symptomatology.

- A- Anti-spike IgA levels in maternal and cord blood samples of SARS-CoV-2 positive mothers divided by 2R, 3R and 3O groups and in non-infected maternal/cord controls (CoV-2⁻, grey), measured by absorbance at 450 nm
- 1090 (OD₄₅₀). Dashed line indicates assay cutoff (CoV- 2^+ n = 60; CoV- 2^- n = 12).
- 1091 B- Anti-spike IgM levels as in A.

1092 C- Anti-spike IgG levels as in A.

- 1093 D- Anti-spike IgA, IgM and IgG levels in plasma of SARS-CoV-2 positive mothers
- 1094 according to the neonate sex (n = 56).
- 1095 E- Paired dyads analysis of anti-RBD IgG in 2R+3R (left; n = 15 dyads) and 3O
- 1096 (right, n = 18 dyads) groups according to neonate sex.
- 1097 F- Correlation between NT50 transfer ratio and elapsed time between diagnosis
- 1098 and delivery (n = 5 dyads).
- 1099 G- Anti-RBD IgG levels in asymptomatic (Asym) and symptomatic (Sym) SARS-
- 1100 CoV-2⁺ infection in all participants (left; n = 50) or in 3O group only (right; n = 35).
- 1101 H- NT50 in asymptomatic (Asym) and symptomatic (Sym) individuals in all SARS-
- 1102 CoV-2⁺ mothers (left; n = 50) or in 3O group only (right; n = 35).
- 1103 I- Correlation between maternal NT50 and anti-spike IgA in 3O group (n = 35).
- 1104 J- Correlation between maternal anti-spike IgA and IgG levels in 3O group (n =
- 1105 35).
- 1106 K- Correlation between maternal NT50 and anti-spike IgA in 2R+3R groups (n =1107 15).
- 1108 L- Correlation between maternal anti-spike IgG and IgA levels in 2R+3R groups1109 (n = 15).
- 1110 p values *p < 0.05, **p < 0.01, ****p < 0.0001; ns, not significant were determined
- 1111 by Kruskal-Wallis test (A, B, C), unpaired t test (D), Mann-Whitney test (D, F, G)
- 1112 parametric paired t test (E), Pearson correlation (H) and Sperman correlation (I-
- 1113 L). Effect size measures +++high, ++medium, +small were determined by η^2 = eta-
- 1114 squared (A, B, C) d = Cohen's d (D, E) and r = correlation coefficient r (D, F, G).
- 1115

1116 Figure S2- Long-term expansion of CXCR5⁺CD4⁺ T cells in maternal SARS-

1117 CoV-2 infection.

- 1118 A- Gating strategy for CD3⁻CD19⁺IgD⁻ B cells (left); for CD69⁺, CCR6⁺ and
- 1119 CXCR5⁺ CD3⁺CD4⁺ T cells (middle); and for CD3⁻CD56⁺ NK cells (right).
- 1120 B- Frequency of circulating B cells in SARS-CoV-2 recovered (2R+3R; n = 14)
- and in vaccinated participants (n = 6).
- 1122 C- Frequency of CD4⁺ T cells as in B.
- 1123 D- Frequency of CD69⁺CD4⁺ T cells as in B.
- 1124 E- Frequency of CXCR5⁺CD4⁺ T cells as in B.
- 1125 F- Frequency of CCR6⁺CD4⁺ T cells as in B.
- 1126 G- Paired dyad analysis of the frequency of CXCR5+CD4+ T cells in SARS-CoV-
- 1127 2 recovered participants (2R+3R; n = 8 dyads).
- 1128 H- As in G for CCR6⁺CD4⁺ T cells (n = 10 dyads).
- 1129 I- Correlation between the frequency of maternal CXCR5⁺CD4⁺ T cells and the
- 1130 elapsed time between diagnosis and delivery in asymptomatic (left) and
- 1131 symptomatic (right) individuals (n = 25).
- 1132 J- Correlation between maternal anti-spike IgG levels and the frequency of
- 1133 CXCR5⁺CD4⁺ T cells in 2R+3R group (n = 10).
- 1134 K- As in J for maternal anti-spike IgA levels.
- 1135 L- As in J for maternal anti-spike IgM levels.
- 1136 p values *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant were determined
- 1137 by Mann-Whitney test (B, E, F), unpaired t test (C, D), non-parametric paired
- 1138 Wilcoxon test (G, H), Pearson correlation (I, J) and Spearman correlation (K, L).
- 1139 Effect size measures +++high, ++medium, +small were determined by r =
- 1140 correlation coefficient r (B, E, F, G, H) and d = Cohen's d (C, D).

1141

1142 Figure S3-Gestational age matched inflammatory profile in SARS-CoV-2

1143 infected and COVID-19 vaccinated individuals.

- 1144 A- Correlation between IFN-γ and IL-12p70 concentration in maternal plasma (n
- 1145 = 58).
- 1146 B- Correlation between IL-17A and IL-23 concentration in maternal plasma (n =
- 1147 58).
- 1148 C- Correlation between IL-18 and IL-23 concentration in maternal plasma (n =
- 1149 58).
- 1150 D- Plasma concentration in ng/mL of IFN-α2, IFN-γ, IL-17A, IL-1β, IL-33, IL-6,
- 1151 TNF-α, IL-18, IL-10, IL-12p70, IL-23, IL-10 and MCP-1 in gestational age-
- 1152 matched infected (CoV- 2^+ n = 20) and vaccinated (Vac n = 6) individuals.
- 1153 E- Correlation between maternal anti-spike IgM levels and IL-6 concentration in
- 1154 maternal plasma diagnosed within 7 days of delivery (n = 17).
- 1155 F- As in E for IL-23 concentration (n = 17).
- 1156 G- Correlation between maternal IL-6 concentration and NK cell frequency in 3O
- 1157 group (n = 36).
- 1158 H- As in G for IL-23 concentration.
- p values *p < 0.05, **p < 0.01, ****p < 0.001; ns, not significant were determined by Spearman correlation (A-C, E-H) and Mann-Whitney test (D). Effect size measures ***high, **medium, *small were determined by r = correlationcoefficient r (D).
- 1163

1164

- 1166 **Table 1:** Demographic and clinical data of pregnant women infected with SARS-CoV-2
- 1167 (CoV-2⁺) categorized between asymptomatic and symptomatic.

	Asymptomatic (n = 30)	Symptomatic (n = 30)
Age categories n (%)		
18-26	9 (30%)	7 (23.3%)
27-33	11 (36.7%)	15 (50%)
34-40	10 (33.3%)	8 (26.7%)
Ethnicity n (%)		
African	9 (30%)	4 (13.3%)
Asian	9 (30%)	3 (10%)
Caucasian	11 (36.7%)	21 (70%)
Romani	0	1 (3.3%)
Unretrieved	1 (3.3%)	1 (3.3%)
Comorbidities n (%)		
Anaemia	3 (10%)	1 (3.3%)
Cardiovascular diseases	2 (6.7%)	1 (3.3%)
Endocrine System	2 (6.7%)	2 (6.7%)
Pulmonary diseases	0	4 (13.3%)
Obesity	3 (10%)	4 (13.3%)
Others	2 (6.7%)	3 (10%)
None	18 (60%)	15 (50%)
Delivery Mode n (%)		
Vaginal	9 (30%)	10 (33.3)
Caesarean	17 (56.7%)	13 (43.3%)
Forceps	3 (10%)	7 (23.3)
Unretrieved	1 (3.3%)	0
Cord Clamping n (%)		
Delayed	14 (46.7%)	14 (46.7%)
Immediate	10 (33.3%)	12 (40%)
Unknown	6 (20%)	4 (13.3%)
SARS-CoV-2 positive PCR in		
mothers	100%	100%
SARS-CoV-2 PCR in new-born		
n (%)		
Negative	26 (86.7%)	20 (66.7%)
Positive	2 (6.7%)	1 (3.3%)
No PCR	2 (6.7%)	9 (30%)
Gender new-born n (%)		
Female	14 (46.7%)	14 (46.7%)
Male	16 (53.3%)	14 (46.7%)
Unretrieved	0	2 (6.7%)

Weight new-born, g, n (%) 2 (6.7%) 3 (10%) 2501 -3000 13 (43.3%) 9 (30%) 3001 -4000 14 (46.7%) 15 (50%) 34000 1 (3.3%) 2 (6.7%) Unretrieved 0 1 (3.3%) Diagnostic Trimester n (%) Second (recovered at delivery) - 3R 3 (10%) 6 (20%) Third (recovered at delivery) - 3R 3 (10%) 6 (20%) 1 (3.3%) delivery) - 30 25 (83.3%) 15 (50%) 15 (50%) Sick Contact n (%) Yes 9 (30%) 18 (60%) 21 (70%) Unknown 2 (6.7%) 9 (30%) 18 (60%) 21 (70%) Unknown 2 (6.7%) 0 1 (3.3%) No 18 (60%) 21 (70%) 10 (33.3%) No 29 (96.7%) 29 (96.7%) 29 (96.7%) Unknown 1 (3.3%) 0 0 Yes 0 4 (13.3%) 0 No 29 (96.7%) 29 (96.7%) 29 (96.7%) Unknown 1 (3.3%) 0 0				
2501-3000 13 (43.3%) 9 (30%) 3001-4000 14 (46.7%) 15 (50%) >4000 1 (3.3%) 2 (6.7%) Unretrieved 0 1 (3.3%) Diagnostic Trimester n (%) Second (recovered at delivery) - 2R	Weight new-born, g, n (%)			
3001-4000 $14 (46.7%)$ $15 (50%)$ >4000 $1 (3.3%)$ $2 (6.7%)$ Unretrieved0 $1 (3.3%)$ Diagnostic Trimester n (%) $8 (6.7%)$ $1 (3.3%)$ Second (recovered at delivery) - 2R $1 (3.7%)$ $6 (20%)$ Third (recovered at delivery) - 3R $3 (10%)$ $6 (20%)$ Third (ongoing infection at delivery) - 30 $2 (6.7%)$ $9 (30%)$ Sick Contact n (%) $9 (30%)$ $9 (30%)$ Yes10 (33.3%) $9 (30%)$ No18 (60%)21 (70%)Unknown $2 (6.7%)$ 0 Invasive Ventilation n (%) $9 (30%)$ Yes0 $1 (3.3%)$ No29 (96.7%)29 (96.7%)Unknown $1 (3.3%)$ 0 Oxygen Support n (%) $9 (30%)$ Yes0 $4 (13.3%)$ No29 (96.7%)26 (86.7%)Unknown $1 (3.3%)$ 0 Tinging of Pneumonia n (%) $9 (30%)$ Yes0 $4 (13.3%)$ No28 (93.3%)26 (86.7%)Unknown $2 (6.7%)$ 0 Yes – intensive care $0 (1 (3.3%)$ Yes – no intensive care $0 (3 (10%)$ No $28 (93.3%)$ $26 (86.7%)$	<2500	2 (6.7%)	3 (10%)	
>4000 1 (3.3%) 2 (6.7%) Unretrieved 0 1 (3.3%) Diagnostic Trimester n (%) Second (recovered at delivery) - 3 - Second (recovered at delivery) - 3R 3 (10%) 6 (20%) Third (recovered at delivery) - 3R 3 (10%) 6 (20%) Third (ongoing infection at d 2 (6.7%) 9 (30%) - delivery) - 3O 25 (83.3%) 15 (50%) Sick Contact n (%) 9 - Yes 10 (33.3%) 9 (30%) No 18 (60%) 21 (70%) Unknown 2 (6.7%) 0 Invasive Ventilation n (%) 0 - Yes 0 1 (3.3%) 0 No 29 (96.7%) 29 (96.7%) 29 (96.7%) Unknown 1 (3.3%) 0 - No 29 (96.7%) 26 (86.7%) - Unknown 1 (3.3%) 0 - Ves 0 4 (13.3%) 0 Invasive Ventilation n (%) 0 - - <tr< td=""><td>2501-3000</td><td>13 (43.3%)</td><td>9 (30%)</td></tr<>	2501-3000	13 (43.3%)	9 (30%)	
Unretrieved 0 1 (3.3%) Diagnostic Trimester n (%) Second (recovered at delivery) - 2R Third (recovered at delivery) - 3R 3 (10%) 6 (20%) Third (ongoing infection at delivery) - 3O 3 (10%) 6 (20%) Third (ongoing infection at delivery) - 3O 25 (83.3%) 15 (50%) Sick Contact n (%) 9 (30%) 9 (30%) Yes 10 (33.3%) 9 (30%) No 18 (60%) 21 (70%) Unknown 2 (6.7%) 0 Invasive Ventilation n (%) 9 9 Yes 0 1 (3.3%) No 29 (96.7%) 29 (96.7%) Unknown 1 (3.3%) 0 Oxygen Support n (%) 0 4 (13.3%) Yes 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 No 29 (96.7%) 26 (86.7%) Unknown 2 (6.7%) 0 Ves 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) <t< td=""><td>3001-4000</td><td>14 (46.7%)</td><td>15 (50%)</td></t<>	3001-4000	14 (46.7%)	15 (50%)	
Diagnostic Trimester n (%) Second (recovered at delivery) - 2R Third (recovered at delivery) - 3R 3 (10%) 6 (20%) Third (ongoing infection at delivery) - 3O 2 (6.7%) 9 (30%) Sick Contact n (%) Yes 10 (33.3%) 9 (30%) No 18 (60%) 21 (70%) Unknown 2 (6.7%) 0 Invasive Ventilation n (%) Yes 0 1 (3.3%) No 29 (96.7%) 29 (96.7%) Unknown 1 (3.3%) 0 Oxygen Support n (%) Yes 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Oxygen Support n (%) Yes 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 Monown 2 (6.7%) 0 Ves 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 Ves – intensive care 0 1 (3.3%) Yes – no intensive care 0 3 (10%) </td <td>>4000</td> <td>1 (3.3%)</td> <td>2 (6.7%)</td>	>4000	1 (3.3%)	2 (6.7%)	
Second (recovered at delivery) - 2R 3 (10%) 6 (20%) Third (recovered at delivery) - 3R 3 (10%) 6 (20%) Third (ongoing infection at 2 (6.7%) 9 (30%) delivery) - 3O 25 (83.3%) 15 (50%) Sick Contact n (%) 9 9 (30%) Yes 10 (33.3%) 9 (30%) No 18 (60%) 21 (70%) Unknown 2 (6.7%) 0 Invasive Ventilation n (%) 9 9 (30%) Yes 0 1 (3.3%) No 29 (96.7%) 29 (96.7%) Unknown 1 (3.3%) 0 Oxygen Support n (%) 29 (96.7%) 26 (86.7%) Yes 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Imaging of Pneumonia n (%) 0 4 (13.3%) Yes 0 4 (13.3%) Unknown 2 (6.7%) 0 Unknown 2 (6.7%) 0 Ves 0 3 (10%)	Unretrieved	0	1 (3.3%)	
delivery) - 2R Image (recovered at delivery) - 3R 3 (10%) 6 (20%) Third (ongoing infection at 2 (6.7%) 9 (30%) delivery) - 30 25 (83.3%) 15 (50%) Sick Contact n (%) 9 (30%) delivery) - 30 25 (83.3%) 15 (50%) Sick Contact n (%) 9 (30%) delivery) - 30 25 (83.3%) 9 (30%) No 18 (60%) 21 (70%) delivery) delivery) - 30 26 (6.7%) 0 Unknown 2 (6.7%) 0 delivery)	Diagnostic Trimester n (%)			
Third (recovered at delivery) - 3R 3 (10%) 6 (20%) Third (ongoing infection at 2 (6.7%) 9 (30%) delivery) - 3O 25 (83.3%) 15 (50%) Sick Contact n (%) 7 9 (30%) Yes 10 (33.3%) 9 (30%) No 18 (60%) 21 (70%) Unknown 2 (6.7%) 0 Invasive Ventilation n (%) 7 9 Yes 0 1 (3.3%) No 29 (96.7%) 29 (96.7%) Unknown 1 (3.3%) 0 Yes 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Yes 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 Yes 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 Yes 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 Yes<	Second (recovered at			
3R $3(10%)$ $6(20%)$ Third (ongoing infection at delivery) - 3O $2(6.7%)$ $9(30%)$ $25(83.3%)$ $15(50%)$ Sick Contact n (%) $25(83.3%)$ $9(30%)$ Yes $10(33.3%)$ $9(30%)$ No $18(60%)$ $21(70%)$ Unknown $2(6.7%)$ 0 Invasive Ventilation n (%) $29(96.7%)$ $29(96.7%)$ Yes 0 $1(3.3%)$ 0 No $29(96.7%)$ $29(96.7%)$ $29(96.7%)$ Unknown $1(3.3%)$ 0 Ves 0 $4(13.3%)$ No $29(96.7%)$ $26(86.7%)$ Unknown $1(3.3%)$ 0 Yes 0 $4(13.3%)$ No $29(96.7%)$ $26(86.7%)$ Unknown $1(3.3%)$ 0 Imaging of Pneumonia n (%) $28(93.3%)$ $26(86.7%)$ Yes 0 $4(13.3%)$ No $28(93.3%)$ $26(86.7%)$ Unknown $2(6.7%)$ 0 COVID-19 hospitalization n (%) $(%)$ $3(10%)$ Yes – no intensive care 0 $3(10%)$ No $28(93.3%)$ $26(86.7%)$	delivery) - 2R			
Third (ongoing infection at delivery) - 30 2 (6.7%) 9 (30%) Sick Contact n (%) 25 (83.3%) 15 (50%) Yes 10 (33.3%) 9 (30%) No 18 (60%) 21 (70%) Unknown 2 (6.7%) 0 Invasive Ventilation n (%) 7 0 Yes 0 1 (3.3%) No 29 (96.7%) 29 (96.7%) Unknown 1 (3.3%) 0 Oxygen Support n (%) 7 7 Yes 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Yes 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Ves 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 Ves 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 <td>Third (recovered at delivery) -</td> <td></td> <td></td>	Third (recovered at delivery) -			
delivery) - 3O 25 (83.3%) 15 (50%) Sick Contact n (%) 10 (33.3%) 9 (30%) No 18 (60%) 21 (70%) Unknown 2 (6.7%) 0 Invasive Ventilation n (%) 7 9 Yes 0 1 (3.3%) No 29 (96.7%) 29 (96.7%) Unknown 1 (3.3%) 0 Oxygen Support n (%) 0 4 (13.3%) Yes 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Oxygen Support n (%) 7 9 Yes 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Imaging of Pneumonia n (%) 7 9 Yes 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 COVID-19 hospitalization n 7 7 (%) 7 3 (10%) <td>3R</td> <td>3 (10%)</td> <td>6 (20%)</td>	3R	3 (10%)	6 (20%)	
Sick Contact n (%) 10 (33.3%) 9 (30%) Yes 10 (33.3%) 9 (30%) No 18 (60%) 21 (70%) Unknown 2 (6.7%) 0 Invasive Ventilation n (%) 7 0 Yes 0 1 (3.3%) 0 No 29 (96.7%) 29 (96.7%) 29 (96.7%) Unknown 1 (3.3%) 0 0 Oxygen Support n (%) 7 26 (86.7%) 0 Yes 0 4 (13.3%) 0 No 29 (96.7%) 26 (86.7%) 0 Unknown 1 (3.3%) 0 0 Maging of Pneumonia n (%) 29 (96.7%) 26 (86.7%) 0 Ves 0 4 (13.3%) 0 0 Imaging of Pneumonia n (%) 28 (93.3%) 26 (86.7%) 0 Ves 0 2 (6.7%) 0 0 COVID-19 hospitalization n (%) 7 0 1 (3.3%) Yes – no intensive care 0 3 (10%) 3	Third (ongoing infection at	2 (6.7%)	9 (30%)	
Yes 10 (33.3%) 9 (30%) No 18 (60%) 21 (70%) Unknown 2 (6.7%) 0 Invasive Ventilation n (%) 7 0 Yes 0 1 (3.3%) No 29 (96.7%) 29 (96.7%) Unknown 1 (3.3%) 0 Oxygen Support n (%) 7 26 (86.7%) Yes 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Yes 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Imaging of Pneumonia n (%) 7 7 Yes 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 COVID-19 hospitalization n 7 7 (%) 7 0 Yes – intensive care 0 1 (3.3%) Yes – no intensive care 0 3 (10%)	delivery) - 30	25 (83.3%)	15 (50%)	
No 18 (60%) 21 (70%) Unknown 2 (6.7%) 0 Invasive Ventilation n (%) 0 Yes 0 1 (3.3%) No 29 (96.7%) 29 (96.7%) Unknown 1 (3.3%) 0 Oxygen Support n (%) 0 Yes 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Yes 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Imaging of Pneumonia n (%) 4 (13.3%) Yes 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 COVID-19 hospitalization n (%) 1 (3.3%) Yes – intensive care 0 1 (3.3%) Yes – no intensive care 0 3 (10%) No 28 (93.3%) 26 (86.7%)	Sick Contact n (%)			
Unknown $2 (6.7\%)$ 0Invasive Ventilation n (%) $2 (6.7\%)$ 0Yes0 $1 (3.3\%)$ No $29 (96.7\%)$ $29 (96.7\%)$ Unknown $1 (3.3\%)$ 0Oxygen Support n (%) 0 $4 (13.3\%)$ Yes0 $4 (13.3\%)$ No $29 (96.7\%)$ $26 (86.7\%)$ Unknown $1 (3.3\%)$ 0Maging of Pneumonia n (%) 0 $4 (13.3\%)$ Yes0 $4 (13.3\%)$ No $28 (93.3\%)$ $26 (86.7\%)$ Unknown $2 (6.7\%)$ 0 COVID-19 hospitalization n $(\%)$ 0 Yes - intensive care0 $1 (3.3\%)$ Yes - no intensive care0 $3 (10\%)$ No $28 (93.3\%)$ $26 (86.7\%)$	Yes	10 (33.3%)	9 (30%)	
Invasive Ventilation n (%) Yes01 (3.3%)Yes01 (3.3%)No29 (96.7%)29 (96.7%)Unknown1 (3.3%)0Oxygen Support n (%) Yes04 (13.3%)No29 (96.7%)26 (86.7%)Unknown1 (3.3%)0Imaging of Pneumonia n (%) Yes04 (13.3%)No28 (93.3%)26 (86.7%)Unknown2 (6.7%)0COVID-19 hospitalization n (%) Yes - no intensive care01 (3.3%)No28 (93.3%)26 (86.7%)No28 (93.3%)3 (10%)No28 (93.3%)26 (86.7%)	No	18 (60%)	21 (70%)	
Yes01 (3.3%)No29 (96.7%)29 (96.7%)Unknown1 (3.3%)0Oxygen Support n (%)Yes04 (13.3%)No29 (96.7%)26 (86.7%)Unknown1 (3.3%)0Imaging of Pneumonia n (%)Yes04 (13.3%)No28 (93.3%)26 (86.7%)Unknown2 (6.7%)0COVID-19 hospitalization n (%)1 (3.3%)Yes – intensive care01 (3.3%)Yes – no intensive care03 (10%)No28 (93.3%)26 (86.7%)	Unknown	2 (6.7%)	0	
No29 (96.7%)29 (96.7%)Unknown1 (3.3%)0Oxygen Support n (%)Yes04 (13.3%)No29 (96.7%)26 (86.7%)Unknown1 (3.3%)0Imaging of Pneumonia n (%)Yes04 (13.3%)No28 (93.3%)26 (86.7%)Unknown2 (6.7%)0COVID-19 hospitalization n(%)1 (3.3%)0Yes – intensive care01 (3.3%)Yes – no intensive care03 (10%)No28 (93.3%)26 (86.7%)	Invasive Ventilation n (%)			
Unknown 1 (3.3%) 0 Oxygen Support n (%) Yes 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Imaging of Pneumonia n (%) Yes 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 22 (6.7%) 0 Ves 0 No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 COVID-19 hospitalization n (%) 1 (3.3%) Yes – intensive care 0 1 (3.3%) Yes – no intensive care 0 3 (10%) No 28 (93.3%) 26 (86.7%)	Yes	0	1 (3.3%)	
Oxygen Support n (%) No 0 4 (13.3%) No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Imaging of Pneumonia n (%) 7 7 Yes 0 4 (13.3%) No 1 (3.3%) 0 Imaging of Pneumonia n (%) 7 7 Yes 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 COVID-19 hospitalization n 7 7 (%) 1 (3.3%) 1 (3.3%) Yes – intensive care 0 1 (3.3%) Yes – no intensive care 0 3 (10%) No 28 (93.3%) 26 (86.7%)	No	29 (96.7%)	29 (96.7%)	
Yes04 (13.3%)No29 (96.7%)26 (86.7%)Unknown1 (3.3%)0Imaging of Pneumonia n (%)Yes04 (13.3%)No28 (93.3%)26 (86.7%)Unknown2 (6.7%)0COVID-19 hospitalization n(%)1 (3.3%)1 (3.3%)Yes – intensive care01 (3.3%)Yes – no intensive care03 (10%)No28 (93.3%)26 (86.7%)	Unknown	1 (3.3%)	0	
No 29 (96.7%) 26 (86.7%) Unknown 1 (3.3%) 0 Imaging of Pneumonia n (%) 7 7 Yes 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 COVID-19 hospitalization n 0 0 (%) 1 1 1 Yes – intensive care 0 1 1 No 28 (93.3%) 26 (86.7%) 1 Yes – intensive care 0 3 1 Yes – no intensive care 0 3 3 No 28 (93.3%) 26 (86.7%)	Oxygen Support n (%)			
Unknown 1 (3.3%) 0 Imaging of Pneumonia n (%) 0 4 (13.3%) Yes 0 4 (13.3%) 0 No 28 (93.3%) 26 (86.7%) 0 Unknown 2 (6.7%) 0 0 COVID-19 hospitalization n (%) 1 (3.3%) 1 (3.3%) 1 (3.3%) Yes – intensive care 0 1 (3.3%) 1 (3.3%) Yes – no intensive care 0 3 (10%) 3 (10%) No 28 (93.3%) 26 (86.7%) 26 (86.7%)	Yes	0	4 (13.3%)	
Imaging of Pneumonia n (%) 0 4 (13.3%) Yes 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 COVID-19 hospitalization n (%) 1 (3.3%) Yes – intensive care 0 1 (3.3%) Yes – no intensive care 0 3 (10%) No 28 (93.3%) 26 (86.7%)	No	29 (96.7%)	26 (86.7%)	
Yes 0 4 (13.3%) No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 COVID-19 hospitalization n 0 0 (%) - - Yes – intensive care 0 1 (3.3%) Yes – no intensive care 0 3 (10%) No 28 (93.3%) 26 (86.7%)	Unknown	1 (3.3%)	0	
No 28 (93.3%) 26 (86.7%) Unknown 2 (6.7%) 0 COVID-19 hospitalization n 0 0 (%) - - Yes - intensive care 0 1 (3.3%) Yes - no intensive care 0 3 (10%) No 28 (93.3%) 26 (86.7%)	Imaging of Pneumonia n (%)			
Unknown 2 (6.7%) 0 COVID-19 hospitalization n 0 0 (%) 1 1 1 Yes – intensive care 0 1 (3.3%) 1 Yes – no intensive care 0 3 (10%) 1 No 28 (93.3%) 26 (86.7%)	Yes	0	4 (13.3%)	
COVID-19 hospitalization n Image: Covid and the system Image: Covid and the system <th< td=""><td>No</td><td>28 (93.3%)</td><td>26 (86.7%)</td></th<>	No	28 (93.3%)	26 (86.7%)	
(%) 0 1 (3.3%) Yes - intensive care 0 3 (10%) Yes - no intensive care 0 3 (10%) No 28 (93.3%) 26 (86.7%)	Unknown	2 (6.7%)	0	
Yes – intensive care01 (3.3%)Yes – no intensive care03 (10%)No28 (93.3%)26 (86.7%)				
Yes – no intensive care 0 3 (10%) No 28 (93.3%) 26 (86.7%)	(%)			
No 28 (93.3%) 26 (86.7%)	Yes – intensive care	0	1 (3.3%)	
	Yes – no intensive care	0	3 (10%)	
$1/(2\pi)$	No	28 (93.3%)	26 (86.7%)	
	Unknown	2 (6.7%)	0	

Table 2: Demographic and clinical data of pregnant women negative for SARS-CoV-2

1176 (CoV-2⁻).

SARS-CoV-2 negative PCR in mothers	n=12	
Age Categories n (%)		
18-26	2 (16.7%)	
27-33	5 (41.7%)	
34-40	5 (41.7%)	
Ethnicity n (%)		
African	3 (25%)	
Asian	1 (8.3%)	
Caucasian	7 (58.3%)	
Unretrieved	1 (8.3%)	
Delivery Mode n (%)		
Vaginal	4 (33.3%)	
Caesarean	7 (58.3%)	
Forceps	1 (8.3%)	
Gender new-born n (%)		
Female	3 (25%)	
Male	9 (75%)	
Weight new-born, g, n (%)		
<2500	1 (8.3%)	
2501-3000	1 (8.3%)	
3001-4000	10 (83.3%)	

1189 Table 3: Demographic and clinical data of pregnant women vaccinated with mRNA

1190 COVID-19 BNT162b vaccine.

Vaccinated mothers with mRNA COVID-	2-0		
19 vaccine	n=9		
Age Categories n (%)			
18-26	0		
27-33	4 (44.4%)		
34-40	5 (55.6%)		
Ethnicity n (%)			
Caucasian	9 (100%)		
Delivery Mode n (%)			
Vaginal	2 (22.2%)		
Caesarean	3 (33.4%)		
Forceps	2 (22.2%)		
Unretrieved	2 (22.2%)		
Gender new-born n (%)			
Female	3 (33.4%)		
Male	4 (44.4%)		
Unretrieved	2 (22.2%)		
Weight new-born, g, n (%)			
<2500	0		
2501-3000	2 (22.2%)		
3001-4000	4 (44.4%)		
>4000	1 (11.2%)		
Unretrieved	2 (22.2%)		

Figure 1



Figure 1- Low NAbs in neonates are associated with maternal production of IgM-NAbs and impaired transfer of IgG---NAbs in symptomatic infections.

A- Outline of participants recruitment, divided in CoV-2⁻ group of pregnant women negative for SARS-CoV-2 (n = 12); in 2R group (recovered at delivery) of pregnant women that tested positive for SARS-CoV-2 in the second trimester (n = 9); in 3R group (recovered at delivery) of pregnant women that tested positive for SARS-CoV-2 earlier in the third trimester (n = 11); 30 group (ongoing infection at delivery) of pregnant women that tested positive for SARS-CoV-2 earlier in the third trimester (n = 11); 30 group (ongoing infection at delivery) of pregnant women that tested positive for SARS-CoV-2 at the time of delivery (n = 38); Vac group includes pregnant women that were vaccinated with COVID-19 BNT162b2 vaccine (n = 9).

B- Paired dyad analysis of anti-spike (left) and anti-RBD (right) IgG in 2R, 3R and 3O groups. Dashed line indicates assay cutoff (n = 50 dyads).

C- Paired dyad endpoint titers for anti-spike (left) and anti-RBD (right) IgG in 2R, 3R and 3O groups (n = 50 dyads).

D-Anti-spike (left) and anti-RBD (right) IgG transfer ratio in 2R, 3R and 3O groups (n = 39).

E- Correlation between anti-spike (left) and anti-RBD (right) IgG transfer ratio and elapsed time between diagnosis and delivery (n = 39).

F- Paired dyad analysis of anti-spike IgG levels in 2R+3R and 3O groups according to neonate sex (2R+3R n = 15 dyads; 3O n = 18 dyads).

G- Neutralization curves of maternal plasma from SARS-CoV-2 positive (CoV-2⁺, n = 50) and vaccinated (Vac, n = 6) participants.

H- Neutralization curves of cord plasma from SARS-CoV-2 positive (CoV-2⁺, n = 50) and vaccinated (Vac, n = 6) participants.

I- Neutralization titer (NT50) of maternal plasma from SARS-CoV-2 positive individuals from 2R, 3R and 3O groups; nd: not detectable (n = 50).

J- NT50 paired dyad analysis in SARS-CoV-2 positive (CoV-2⁺, n = 50) and vaccinated participants (Vac, n= 6).

K- Anti-spike (left) and anti-RBD (right) IgG transfer ratio in 3O group in function of the presence (Sym) or absence (Asym) of symptoms (n = 24).

L- Correlation between maternal neutralization titers (NT50) and anti-spike IgG (left) or anti-spike IgM (right) in 3O group (n = 35).

M- Correlation between maternal anti-spike IgM and IgG levels in 3O group (n = 35).

N- Maternal NT50 in function of the presence of anti-spike IgG and/or IgM antibodies in 3O group (n = 35).

O- Correlation between maternal neutralization titers (NT50) and anti-spike IgG (left) or anti-spike IgM (right) in 2R+3R groups (n = 15).

P- Correlation between maternal anti-spike IgM and IgG levels in 2R+3R groups (n = 15).

Q- Maternal NT50 in function of the presence of anti-spike IgG and/or IgM antibodies in 2R+3R groups (n = 15)

R- Correlation between maternal NT50 and anti-spike IgG (orange), IgA (green) and IgM (purple) in vaccinated group (n = 6).

nd: not detectable; p values *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant were determined by parametric paired t test (B, C, F, J), non-parametric paired Wilcoxon test (B, C, J), unpaired t test (K), Mann-Whitney test (J, K, Q), ordinary ANOVA, post hoc Holm-Sidak (D), Kruskal-Wallis test, post hoc Dunn's (I, N), Pearson correlation (E, O) and Spearman correlation (L, M, P, R). Effect size measures ***high, **medium, *small were determined by d = Cohen's d (B, C, F, J, K), r = correlation coefficient r (B, C, J, I, K, M, Q) and η^2 = eta-squared (D, I, N).



Figure 2- Asymptomatic maternal infection is associated with increased early immune response comprised by anti-spike IgM and NK cells.

A- Maternal B cell frequency from 3O group in function of the presence (Sym) or absence (Asym) of symptoms (n = 23).

- B- Frequency of IgD⁻ B cells as in A.
- C- Frequency of CD4⁺ T cells as in A.
- D- Frequency of CD69⁺CD4⁺ T cells as in A.
- E- Frequency of CCR6⁺CD4⁺ T cell as in A.
- F- Frequency of CXCR5⁺CD4⁺ T cell as in A.

G- Maternal NK cell frequency in participants diagnosed for SARS-CoV-2 within 7 days of delivery in asymptomatic (Asym) and symptomatic (Sym) individuals (n = 17).

- H- Cord blood NK cell frequency from participants diagnosed for SARS-CoV-2 within 7 days of delivery, in function of the presence (Sym) or absence (Asym) of symptoms (n = 17).
- I- Maternal anti-spike IgM levels as in G.
- J- Cord blood NK cell frequency upon either immediate or delayed umbilical cord clamping, in 3O group (n = 21).
- K- Cord blood B cell frequency as in J.
- L- Cord blood CD4⁺ T cell frequency J.
- M- Cord blood NK cell frequency upon either immediate or delayed umbilical cord clamping, in 2R+3R group (n = 10).
- p values *p < 0.05; ns, not significant were determined by unpaired t test (A, B, C, F, H J, K, L), Mann-Whitney test (D, E, G, M). Effect size measures ***high, **medium, *small were determined by d = Cohen's d (A, B, C, F, H, J, K, L), r = correlation coefficient r (D, E, G, M).



Figure 3- Maternal inflammatory response balances antibody placental transfer with NK cell expansion.

- A- Maternal plasma concentration (ng/mL) of IFN- α 2, IFN- γ , IL-17A, IL-1 β , IL-33, IL-6, TNF- α , IL-18, IL-10, IL-12p70, IL-23, IL-10 and MCP-1 in recovered (2R+3R, n = 20) and ongoing (30, n = 38) infections.
- B- Correlation between maternal concentration of IFN- α 2, MCP-1, IL-6, IL-18 and elapsed time between diagnosis and delivery (n = 58).
- C- Correlation between anti-RBD IgG transfer ratio and IL-6 concentration in maternal plasma (n = 39).
- D- Correlation between anti-RBD IgG transfer ratio and IL-10 concentration in maternal plasma in the 3O group (n = 24).
- E- Correlation between anti-RBD IgG transfer ratio and IL-23 concentration in maternal plasma in the 3O group (n = 24).
- F- Correlation between anti-RBD IgG levels and IL-6 concentration in maternal plasma (n = 48).
- G- Correlation between anti-RBD IgG levels and IL-10 concentration in maternal plasma in the 3O group (n = 28).
- H- Correlation between anti-RBD IgG levels and IL-23 concentration in maternal plasma in the 3O group (n = 28).
- I- Correlation between NT50 and IL-6 (left) or IL-10 (right) concentration in maternal plasma in the 3O group (n = 19).
- J- Correlation between NT50 and IL-23 concentration in maternal plasma in the 3O group (n = 19).
- K- Correlation between anti-spike IgM levels and IL-10 concentration in maternal plasma within 7 days between diagnosis and delivery (n = 17).
- L- Correlation between IL-10 concentration and NK cell frequency in 3O group (n = 36).

p values *p < 0.05; ns, not significant were determined by Mann-Whitney test (A), Spearman correlation (B, F, I, K, L) and Pearson correlation (C, D, E, G, H). Effect size measures ***high, **medium, *small were determined by r = correlation coefficient r (A).

Figure 4



Figure 4- Higher concentration of at least one inflammatory cytokine in the cord blood in half of mother:neonate dyads.

A- Plasma concentration (ng/mL) of IFN- α 2, IFN- γ , IL-17A, IL-1 β , IL-33, IL-6, TNF- α , IL-18, IL-10, IL-12p70, IL-23, IL-10 and MCP-1 in paired mother: neonate dyads (n = 50 dyads).

B- Cytokine ratio between cord and maternal blood (n=27 dyads).

C- Polar plots depicting the cytokine profile of neonates born to asymptomatic (left) and symptomatic (right) mothers, in dyads with cord/maternal ratio>1.5 (n=27 dyads).

D- Polar plots depicting the cytokine profile of female (left) and male (right) neonates, in dyads with cord/maternal ratio>1.5 (n=27 dyads).

E- Paired dyad analysis of anti-spike IgA levels. Dashed line indicates assay cutoff (n = 50 dyads).

- F- Paired dyad analysis of anti-spike IgM levels. Dashed line indicated assay cutoff (n = 50 dyads).
- G- Endpoint titers for anti-spike IgA measured in paired dyads; nd: not detectable (n = 50 dyads).
- H- Endpoint titers for anti-spike IgM measured in paired dyads; nd: not detectable (n = 50 dyads).
- I- Frequency of IgD⁻ B cells in paired dyads in 2R, 3R and 3O groups (n=30 dyads).
- J- Cytokine ratio between cord and maternal blood.

p values *p < 0.05, ***p < 0.001, ****p < 0.0001; ns, not significant were determined by non-parametric paired Wilcoxon test (A, E, F, I) and parametric paired t test (I). Effect size measures ***high, **medium, *small were determined by r = correlation coefficient r (A, E, F, I) and d = Cohen's d (I).

Figure S1



Figure S1- Antibody levels in maternal:neonate dyads classified by sex of the neonate and symptomatology.

A- Anti-spike IgA levels in maternal and cord blood samples of SARS-CoV-2 positive mothers divided by 2R, 3R and 3O groups and in non-infected maternal/cord controls (CoV-2⁻, grey), measured by absorbance at 450 nm (OD₄₅₀). Dashed line indicates assay cutoff (CoV-2⁺ n = 60; CoV-2⁻ n = 12).

B-Anti-spike IgM levels as in A.

C-Anti-spike IgG levels as in A.

D-Anti-spike IgA, IgM and IgG levels in plasma of SARS-CoV-2 positive mothers according to the neonate sex (n = 56).

E- Paired dyads analysis of anti-RBD IgG in 2R+3R (left; n = 15 dyads) and 3O (right, n = 18 dyads) groups according to neonate sex.

F- Correlation between NT50 transfer ratio and elapsed time between diagnosis and delivery (n = 5 dyads).

G- Anti-RBD IgG levels in asymptomatic (Asym) and symptomatic (Sym) SARS-CoV-2⁺ infection in all participants (left; n = 50) or in 30 group only (right; n = 35).

H- NT50 in asymptomatic (Asym) and symptomatic (Sym) individuals in all SARS-CoV-2⁺ mothers (left; n = 50) or in 30 group only (right; n = 35).

I- Correlation between maternal NT50 and anti-spike IgA in 3O group (n = 35).

- J- Correlation between maternal anti-spike IgA and IgG levels in 3O group (n = 35).
- K- Correlation between maternal NT50 and anti-spike IgA in 2R+3R groups (n = 15).
- L- Correlation between maternal anti-spike IgG and IgA levels in 2R+3R groups (n = 15).

p values *p < 0.05, **p < 0.01, ****p < 0.0001; ns, not significant were determined by Kruskal-Wallis test (A, B, C), unpaired t test (D), Mann-Whitney test (D, F, G) parametric paired t test (E), Pearson correlation (H) and Sperman correlation (I-L). Effect size measures ***high, **medium, *small were determined by η² = eta-squared (A, B, C) d = Cohen's d (D, E) and r = correlation coefficient r (D, F, G).

Figure S2



Figure S2- Long-term expansion of CXCR5⁺CD4⁺ T cells in maternal SARS-CoV-2 infection.

A- Gating strategy for CD3⁻CD19⁺IgD⁻ B cells (left); for CD69⁺, CCR6⁺ and CXCR5⁺ CD3⁺CD4⁺ T cells (middle); and for CD3--CD56⁺ NK cells (right).

- B- Frequency of circulating B cells in SARS-CoV-2 recovered (2R+3R; n = 14) and in vaccinated participants (n = 6).
- C- Frequency of CD4⁺ T cells as in B.
- D- Frequency of CD69⁺CD4⁺ T cells as in B.
- E- Frequency of CXCR5⁺CD4⁺ T cells as in B.
- F- Frequency of CCR6⁺CD4⁺ T cells as in B.

G- Paired dyad analysis of the frequency of CXCR5⁺CD4⁺ T cells in SARS-CoV-2 recovered participants (2R+3R; n = 8 dyads).

H- As in G for CCR6⁺CD4⁺ T cells (n = 10 dyads).

I- Correlation between the frequency of maternal CXCR5⁺CD4⁺ T cells and the elapsed time between diagnosis and delivery in asymptomatic (left) and symptomatic (right) individuals (n = 25).

J- Correlation between maternal anti-spike IgG levels and the frequency of CXCR5⁺CD4⁺ T cells in 2R+3R group (n = 10).

K- As in J for maternal anti-spike IgA levels.

L- As in J for maternal anti-spike IgM levels.

p values *p < 0.05, **p < 0.01, ***p <0.001; ns, not significant were determined by Mann-Whitney test (B, E, F), unpaired t test (C, D), non-parametric paired Wilcoxon test (G, H), Pearson correlation (I, J) and Spearman correlation (K, L). Effect size measures ***high, **medium, *small were determined by r = correlation coefficient r (B, E, F, G, H) and d = Cohen's d (C, D).

Figure S3



Figure S3-Gestational age matched inflammatory profile in SARS-CoV-2 infected and COVID-19 vaccinated individuals.

A- Correlation between IFN-γ and IL-12p70 concentration in maternal plasma (n = 58).

B- Correlation between IL-17A and IL-23 concentration in maternal plasma (n = 58).

C- Correlation between IL-18 and IL-23 concentration in maternal plasma (n = 58).

D- Plasma concentration in ng/mL of IFN- α 2, IFN- γ , IL-17A, IL-1 β , IL-33, IL-6, TNF- α , IL-18, IL-10, IL-12p70, IL-23, IL-10 and MCP-1 in gestational age-matched infected (CoV-2⁺ n = 20) and vaccinated (Vac n = 6) individuals.

E- Correlation between maternal anti-spike IgM levels and IL-6 concentration in maternal plasma diagnosed within 7 days of delivery (n = 17).

F-As in E for IL-23 concentration (n = 17).

G- Correlation between maternal IL-6 concentration and NK cell frequency in 3O group (n = 36).

H-As in G for IL-23 concentration.

p values *p < 0.05, **p < 0.01, ****p < 0.0001; ns, not significant were determined by Spearman correlation (A-C, E-H) and Mann-Whitney test (D). Effect size measures ***high, **medium, *small were determined by r = correlation coefficient r (D).